MedGenome Labs Consolidated Financial Statements 2020-21

MEDGENOME LABS LIMITED
Consolidated Financial Statements for period 01/04/2020 to 31/03/2021
[400100] Disclosure of general information about company

Unless otherwise specified, all monetary values are in INR
01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Name of company MEDGENOME LABS LIMITED
Corporate identity number U73100KA2013PLC084414
Permanent account number of entity AAICM5351P
No. 258/A,3rd Floor
Narayana Nethralaya, ,
Narayana Health City,
Address of registered office of company Hosur Road,Bommasandra
, Bangalore , KARNATAKA
, INDIA - 560099
Commercial and
Type of industry Industrial
Number of employees in the company at the end of the financial Year [pure] 485
Whether company has published sustainability report for the financial
No
Year
Period covered by financial statements 2020-21
Date of start of reporting period 01/04/2020 01/04/2019
Date of end of reporting period 31/03/2021 31/03/2020
Nature of report standalone consolidated Consolidated
Content of report Financial Statements
Description of presentation currency INR
Level of rounding used in financial statements Actual
Type of cash flow statement Indirect Method
[400200] Disclosures - Auditors report
Details regarding auditors [Table] ..(1)

Auditors [Axis] 1
01/04/2020
to
31/03/2021
Details regarding auditors [Abstract]
Details regarding auditors [LineItems]
Category of auditor Auditors firm
B S R & Associates
Name of audit firm LLP
Name of auditor signing report Tushar Tibrewal
Firms registration number of audit firm 116231W/W-100024
Membership number of auditor 067829
Maruthi-lnfo Tech,
Address of auditors Centre 11-12/1,
Permanent account number of auditor or auditor's firm AADFB6889R
SRN of form ADT-1 Z99999999
Date of signing audit report by auditors 15/12/2021
Date of signing of balance sheet by auditors 15/12/2021

01/04/2020
to
31/03/2021
Textual information (1)
Disclosure in auditor’s report explanatory [TextBlock] [See below]
Whether companies auditors report order is applicable on company No
Whether auditors' report has been qualified or has any reservations or
No
contains adverse remarks
MEDGENOME LABS LIMITED Consolidated Financial Statements for period 01/04/2020 to 31/03/2021
Disclosure in auditor’s report explanatory [Text Block]
INDEPENDENT AUDITORS REPORT
To the Members of MedGenome Labs Limited
Report on the Audit of Consolidated Financial Statements
Opinion
We have audited the consolidated financial statements of MedGenome Labs Limited (hereinafter referred to as the Holding Company) and its
subsidiary (Holding Company and its subsidiary together referred to as the Group), which comprises the consolidated balance sheet as at 31st
March 2021, and the consolidated statement of profit and loss , and consolidated statement of cash flows for the year then ended, and notes
to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information
(hereinafter referred to as the consolidated financial statements).
In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial
statements give the information required by the Companies Act, 2013 (Act) in the manner so required and give a true and fair view in
conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, as at 31st March
2021, of its consolidated profit and its consolidated cash flows for the year ended on that date.
Basis for Opinion
We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities
under those SAs are further described in the Auditors Responsibilities for the Audit of the Consolidated Financial Statements section of our
report.
We are independent of the Group, in accordance with the ethical requirements that are relevant to our audit of the consolidated financial
statements in terms of the Code of Ethics issued by the Institute of Chartered Accountants of India and the relevant provisions of the Act, and
we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence obtained by us
is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.
Other Information
The Holding Companys management and Board of Directors are responsible for the other information. The other information comprises the
information included in the Holding Companys Board of Directors Report, but does not include the consolidated financial statements and our
auditors report thereon.
2
Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance
conclusion thereon.
In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so,
consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the
audit or otherwise appears to be materially misstated.
The other information is not made available to us at the date of this auditors report. We have nothing to report in this regard.
Managements and Board of Directors Responsibilities for the Consolidated Financial Statements
The Holding Companys Management and Board of Directors are responsible for the preparation and presentation of these consolidated
financial statements in term of the requirements of the Act that give a true and fair view of the consolidated state of affairs, consolidated
profit/ loss and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the
Accounting Standards specified under section 133 of the Act. The respective Management and Board of Directors of the companies included
in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of
the assets of each Company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate
accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of
adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records,
relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material
misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by
the Management and Directors of the Holding Company, as aforesaid.
In preparing the consolidated financial statements, the respective Management and Board of Directors of the companies included in the
Group are responsible for assessing the ability of each Company to continue as a going concern, disclosing, as applicable, matters related to
going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the
Company or to cease operations, or has no realistic alternative but to do so.
The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of
each Company.
Auditors Responsibilities for the Audit of the Consolidated Financial Statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material
misstatement, whether due to fraud or error, and to issue an auditors report that includes our opinion. Reasonable assurance is a high level of
assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.
Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be
expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
3
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.
We also:
Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and
perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our
opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the
circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on the internal financial controls with
reference to consolidated financial statements and the operating effectiveness of such controls based on our audit.
B S R & Associates LLP
Auditors Responsibilities for the Audit of the Consolidated Financial Statements (continued)
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by
the Management and Board of Directors.
Conclude on the appropriateness of Management and Board of Directors use of the going concern basis of accounting in preparing
consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or
conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are
required to draw attention in our auditors report to the related disclosures in the consolidated financial statements or, if such disclosures are
inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors report. However,
future events or conditions may cause the Group entities to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the
consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group to
express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the audit
of financial information of such entities included in the consolidated financial statements of which we are the independent auditors.
We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated
financial statements
4
We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial
statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and
significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding
independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our
independence, and where applicable, related safeguards.
Report on Other Legal and Regulatory Requirements
1. (A) As required by Section 143(3) of the Act, based on our audit, we report, to the extent applicable, that:
a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the
purposes of our audit of the aforesaid consolidated financial statements.
b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements
have been kept so far as it appears from our examination of those books.
c) The consolidated balance sheet, the consolidated statement of profit and loss, and the consolidated statement of cash flows dealt with
by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial
statements.
d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under section 133 of the
Act.
e) On the basis of the written representations received from the directors of the Holding Company as on 31 March 2021 taken on record
by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary company, none of the directors
of the Group companies, incorporated in India is disqualified as on 31 March 2021 from being appointed as a director in terms of Section
164(2) of the Act.
f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company and its
subsidiary company, incorporated in India, and the operating effectiveness of such controls, refer to our separate Report in Annexure A .
5
(B) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and
Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us us:
i. The consolidated financial statements disclose the impact of pending litigations as at 31st March 2021 on the consolidated financial
position of the Group. Refer Note 3.27 (i.e Notes related to contingent liability )to the consolidated financial statements.
ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts during the year ended 31
March 2021.
iii. There are no amounts which are required to be transferred to the Investor Education and Protection Fund by the Holding Company or its
subsidiary company during the year ended 31 March 2021; and
iv. The disclosures regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December
2016 have not been made in the consolidated financial statements since they do not pertain to the financial year ended 31 March 2021.
Report on Other Legal and Regulatory Requirements (continued)
(B) With respect to the matter to be included in the Audit Report under Section 197(16):
In our opinion and according to the information and explanation given to us and based on examination of records of the Company, the
Holding Company and its subsidiary company has not paid/provided for any managerial remuneration to its directors during the year.
Accordingly, the provision of Section 197 is not applicable to the Holding Company and its subsidiary company. The Ministry of Corporate
Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.
for B S R & Associates LLP
Chartered Accountants
Firm's Registration No.: 116231W/W-100024
6
Tushar Tibrewal
Partner
Membership No : 067829
UDIN: 21067829AAAAAO6940
Place: Bengaluru
Date: 15 December 2021
Annexure A to the Independent Auditors report on the consolidated financial statements of MedGenome Labs Limited for the period ended
31st March 2021
Report on the internal financial controls with reference to the aforesaid consolidated financial statements under Clause (i) of Sub-section 3 of
Section 143 of the Companies Act, 2013
(Referred to in paragraph 1(A)(f) under Report on Other Legal and Regulatory Requirements section of our report of even date)
Opinion
In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31st March 2021, we have
audited the internal financial controls with reference to consolidated financial statements of MedGenome Labs Limited (hereinafter referred
to as the Holding Company) and such companies incorporated in India under the Companies Act, 2013 which are its subsidiary company, as
of that date.
In our opinion, the Holding Company and such companies incorporated in India which are its subsidiary company, have, in all material
respects, adequate internal financial controls with reference to consolidated financial statements and such internal financial controls were
operating effectively as at 31st March 2021, based on the internal financial controls with reference to consolidated financial statements
criteria established by such companies considering the essential components of such internal controls stated in the Guidance Note on Audit of
Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the Guidance Note).
Managements Responsibility for Internal Financial Controls
The respective Companys management and the Board of Directors are responsible for establishing and maintaining internal financial controls
with reference to consolidated financial statements based on the criteria established by the respective Company considering the essential
components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of
adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including
7
adherence to the respective companys policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy
and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies
Act, 2013 (hereinafter referred to as the Act).
Auditors Responsibility
Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements based on our
audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the
Act, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements. Those Standards and
the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about
whether adequate internal financial controls with reference to consolidated financial statements were established and maintained and if such
controls operated effectively in all material respects.
Auditors Responsibility (continued)
Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to
consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated
financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements,
assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of the internal controls
based on the assessed risk. The procedures selected depend on the auditors judgement, including the assessment of the risks of material
misstatement of the consolidated financial statements, whether due to fraud or error.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal
financial controls with reference to consolidated financial statements.
Meaning of Internal Financial controls with Reference to Consolidated Financial Statements
A company's internal financial controls with reference to consolidated financial statements is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles. A company's internal financial controls with reference to consolidated financial statements includes
those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of
the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a
material effect on the financial statements.
Inherent Limitations of Internal Financial controls with Reference to consolidated Financial Statements
Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility
of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also,
projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject
to the risk that the internal financial controls with reference to consolidated financial statements may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
For B S R & Associates LLP
Chartered Accountants
Firm Registration No. 116231W/W-100024
8
Tushar Tibrewal
Partner
Membership No.: 067829
UDIN: 21067829AAAAAO6940
Place: Bangalore
Date: 15 December 2021
9
[100100] Balance sheet

31/03/2021 31/03/2020
Balance sheet [Abstract]
Equity and liabilities [Abstract]
Shareholders' funds [Abstract]
Share capital 2,50,92,910 2,50,92,910
Reserves and surplus -19,38,98,881 -36,77,13,159
Money received against share warrants 0 0
Total shareholders' funds -16,88,05,971 -34,26,20,249
Share application money pending allotment 0 0
Minority interest (A) 0

(B) -40,36,359
Non-current liabilities [Abstract]
Long-term borrowings 47,98,49,958 71,11,11,273
Other long-term liabilities 5,41,396 26,55,440
Long-term provisions 2,25,12,573 1,93,97,684
Total non-current liabilities 50,29,03,927 73,31,64,397
Current liabilities [Abstract]
Short-term borrowings 65,28,151 47,10,563
Trade payables (C) 21,26,12,479

11,24,05,074
Other current liabilities 46,96,93,264 45,79,24,282

Short-term provisions 2,13,98,724 1,90,58,784
Total current liabilities 71,02,32,618 59,40,98,703
Total equity and liabilities 104,43,30,574 98,06,06,492
Assets [Abstract]
Non-current assets [Abstract]
Fixed assets [Abstract]
Tangible assets (D) 26,04,05,746 (E) 31,63,28,715
Intangible assets 3,56,671 62,61,769
Total fixed assets 26,07,62,417 32,25,90,484
Non-current investments 0 0
Long-term loans and advances 7,46,42,509 11,23,85,656
Other non-current assets 2,08,04,392 7,33,51,423
Total non-current assets 35,62,09,318 50,83,27,563
Current assets [Abstract]
Current investments 0 0
Inventories 15,31,78,860 8,70,87,270
Trade receivables 30,05,86,556 24,28,65,293
Cash and bank balances 17,35,43,310 9,08,67,684
Short-term loans and advances 4,64,13,243 4,57,99,862
Other current assets 1,43,99,287 56,58,820
Total current assets 68,81,21,256 47,22,78,929
Total assets 104,43,30,574 98,06,06,492
10
Footnotes
(A) Minority interest At the commencement of the year: (4036359) Addition during the year: Nil Less: Amount transferred to
reserves: Nil Loss attributable to minority interest: Nil
(B) Minority interest At the commencement of the year: Nil Addition during the year: 3,50,000 Less: Amount transferred to reserves:
Nil Loss attributable to minority interest: (40,36,359)
(C) Dues to micro and small enterprises (refer 3.35) : Nil Dues to others: 212612479 *Includes payable to related party (Refer 3.28)
Note 3.35: Dues to micro and small suppliers The Ministry of Micro, Small and Medium Enterprises has issued an Office
Memorandum dated August 26, 2008 which recommends that the Micro and Small Enterprises should mention in their
correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum.
Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2021 has been made in the financial
statements based on information received and available with the Company. Further in view of the management, the impact of
interest, if any, that may be payable in accordance with the provisions of the Micro, Small and Medium Enterprises Development
Act is not expected to be material. The Company has not received any claim for interest from any supplier under the Micro, Small
and Medium Enterprises Development Act. As at 31 March 2021 As at 31 March 2020 The principal amount and the interest due
thereon remaining unpaid to any supplier as at the end of each accounting year; - - The amount of interest paid by the buyer as per
the Micro Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006). - - The amounts of the payments made to
micro and small suppliers beyond the appointed day during each accounting year - - The amount of interest accrued and remaining
unpaid at the end of each accounting year - - The amount of further interest remaining due and payable even in the succeeding years,
until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a
deductible expenditure under the MSMED Act, 2006 - - 3.28: Related parties Enterprise where control exists 1.Enterprise where
control exists MedGenome Inc.Holding Company SciGenom Labs Private LimitedEntity controlled by Director Shenoy Care Pvt
Ltd.Entity controlled by Director 2. Key management personnel Mr. Sreedhar SanthoshDirector Ms. Balamani Amma MRDirector
Mr. Mahesh PratapneniDirector Mr. Shankar PrasadDirector Mr. Prasad ShejaleDirector Mr. Padmanbha ShenoyDirector 3. The
following is the summary of transactions with related parties Nature of transaction For the year ended 31 March 2021 For the year
ended 31 March 2020 MedGenome Inc. Advance received 80,90,10,714 24,75,29,250 Revenue from academics and
research69,07,53,080 21,38,40,420 Reimbursement of expense/ professional fee 222,36,973 - Purchase of consumables 1,07,11,469
1,86,50,363 Sreedhar Santhosh Travelling expenses 99,239 12,250 Mahesh Pratapneni Travelling expenses 13,898 19,71,039
Shenoy Care Pvt Ltd. Sequencing Services 2,65,208 - Amount paid against Sequencing Services 62,333 - Loan from Director
Mr.Padmanabha Shenoy - 21,00,000 4. Balances payable to related party as at the balance sheet date: As at 31 March 2021 As at 31
March 2020 MedGenome Inc. Advance from customer28,16,91,249 17,27,20,317 Creditor for expenses 5,18,84,344 1,97,74,914
Shenoy Care Pvt Ltd. Sequencing Services 2,02,875 - Key Management Personnel Loan repayable to : Mr.Padmanabha Shenoy
21,00,000 21,00,000 Travel expenses payable to: Mr. Sreedhar Santhosh64,634 1,395
(D) Rs. 2 has been adjusted to match the total in table.
(E) Rs. 2 has been adjusted to match the total in table.
11
[100400] Cash flow statement, indirect

01/04/2020 01/04/2019
to to 31/03/2019
31/03/2021 31/03/2020
Statement of cash flows [Abstract]
Whether cash flow statement is applicable on company Yes Yes
Cash flows from used in operating activities [Abstract]
Profit before extraordinary items and tax 10,49,58,995 -48,47,64,205
Adjustments for reconcile profit (loss) [Abstract]
Adjustments to profit (loss) [Abstract]
Adjustments for finance costs 4,31,89,689 2,13,10,531
Adjustments for depreciation and amortisation expense 16,18,16,826 19,03,46,816
Adjustments for unrealised foreign exchange losses gains -39,76,481 1,87,44,310
Adjustments for share-based payments 7,28,91,642 0
Other adjustments to reconcile profit (loss) -1,31,88,450 -1,09,63,584
Other adjustments for non-cash items (A) 12,39,450

0
Total adjustments to profit (loss) 26,19,72,676 21,94,38,073

Adjustments for working capital [Abstract]
Adjustments for decrease (increase) in inventories -6,60,91,590 -1,24,80,496
Adjustments for decrease (increase) in trade receivables -5,74,79,643 13,21,26,032
Adjustments for decrease (increase) in other current assets (B) -61,86,000 (C) -38,66,937
Adjustments for increase (decrease) in trade payables (D) 19,66,62,004 (E) 8,12,41,294
Adjustments for increase (decrease) in other current liabilities (F) -21,14,044 (G) -8,79,908
Adjustments for provisions 54,54,829 1,06,46,825
Total adjustments for working capital 7,02,45,556 20,67,86,810
Total adjustments for reconcile profit (loss) 33,22,18,232 42,62,24,883
Net cash flows from (used in) operations 43,71,77,227 -5,85,39,322
Income taxes paid (refund) -2,55,65,979 3,55,94,292
Net cash flows from (used in) operating activities before extraordinary
46,27,43,206 -9,41,33,614
items
Net cash flows from (used in) operating activities 46,27,43,206 -9,41,33,614
Cash flows from used in investing activities [Abstract]
Proceeds from sales of tangible assets 0
(H) 3,48,082
Purchase of tangible assets 9,60,51,352 8,68,26,800
Interest received 86,69,621 1,71,87,186
Income taxes paid (refund) 0 0
Other inflows (outflows) of cash (I) -1,12,80,442 (J) -32,12,750

Net cash flows from (used in) investing activities before extraordinary
-9,86,62,173 -7,25,04,282
items
Net cash flows from (used in) investing activities -9,86,62,173 -7,25,04,282
Cash flows from used in financing activities [Abstract]
Proceeds from issuing other equity instruments 0 3,50,000
Proceeds from issuing debentures notes bonds etc -17,00,00,000 17,00,00,000
Proceeds from borrowings 0

(K) 16,59,03,945
Repayments of borrowings (L) 14,76,61,041 (M) 11,10,04,926
Income taxes paid (refund) 0 0
Other inflows (outflows) of cash (N) -4,31,89,689 (O) -2,13,10,531

Net cash flows from (used in) financing activities before extraordinary
-36,08,50,730 20,39,38,488
items
Net cash flows from (used in) financing activities -36,08,50,730 20,39,38,488
Net increase (decrease) in cash and cash equivalents before effect of
32,30,303 3,73,00,592
exchange rate changes
Effect of exchange rate changes on cash and cash equivalents [Abstract]
Effect of exchange rate changes on cash and cash equivalents (P) 2,72,115 (Q) 6,47,715
Net increase (decrease) in cash and cash equivalents 35,02,418 3,79,48,307
Cash and cash equivalents cash flow statement at end of period 5,91,39,858 5,56,37,440 1,76,89,133
12
Footnotes
(A) Provision for doubtful debt
(B) Change in loans and advances
(C) Change in loans and advances
(D) Change in trade payables and other current liabilities
(E) Change in trade payables and other current liabilities
(F) Change in other long-term liabilities
(G) Change in other long-term liabilities
(H) Disposal of assets
(I) Proceeds from / Investment in term deposits, net
(J) Proceeds from / Investment in term deposits, net
(K) Proceeds from loan from director- 21,00,000 Proceeds from loan taken- 163803945
(L) Repayment of loans
(M) Repayment of loans
(N) Finance cost
(O) Finance cost
(P) Effect of exchange differences on cash and cash equivalents held in foreign currency
(Q) Effect of exchange differences on cash and cash equivalents held in foreign currency
[200100] Notes - Share capital
Disclosure of shareholding more than five per cent in company [Table] ..(1)
Classes of share capital [Axis] Equity shares [Member] Equity shares 1 [Member]
Name of shareholder [Axis] Shareholder 1 [Member] Shareholder 1 [Member]
01/04/2020 01/04/2019
31/03/2021 31/03/2020 to to
31/03/2021 31/03/2020
Disclosure of shareholding more than five per cent in
company [Abstract]
Disclosure of shareholding more than five per cent
in company [LineItems]
Type of share Equity Shares Equity Share
Name of shareholder MedGenome Inc. MedGenome Inc.
Country of incorporation or residence of
UNITED STATES UNITED STATES
shareholder
Number of shares held in company [shares] 24,32,104 [shares] 24,32,104 [shares] 24,32,104 [shares] 24,32,104
Percentage of shareholding in company 96.92% 96.92%
13
Disclosure of classes of share capital [Table] ..(1)

Classes of share capital [Axis] Share capital [Member] Equity shares [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of classes of share capital [Abstract]
Disclosure of classes of share capital [LineItems]
Number of shares authorised [shares] 45,00,000 [shares] 45,00,000 [shares] 45,00,000 [shares] 45,00,000
Value of shares authorised 4,50,00,000 4,50,00,000 4,50,00,000 4,50,00,000
Number of shares issued [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291
Value of shares issued 2,50,92,910 2,50,92,910 2,50,92,910 2,50,92,910
Number of shares subscribed and fully paid [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291
Value of shares subscribed and fully paid 2,50,92,910 2,50,92,910 2,50,92,910 2,50,92,910
Number of shares subscribed but not fully paid [shares] 0 [shares] 0 [shares] 0 [shares] 0
Value of shares subscribed but not fully paid 0 0 0 0
Total number of shares subscribed [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291
Total value of shares subscribed 2,50,92,910 2,50,92,910 2,50,92,910 2,50,92,910
Value of shares paid-up [Abstract]
Number of shares paid-up [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291
Value of shares called 2,50,92,910 2,50,92,910 2,50,92,910 2,50,92,910
Calls unpaid [Abstract]
Calls unpaid by directors and officers
[Abstract]
Calls unpaid by directors 0 0 0 0
Calls unpaid by officers 0 0 0 0
Total calls unpaid by directors and
0 0 0 0
officers
Calls unpaid by others 0 0 0 0
Total calls unpaid 0 0 0 0
Forfeited shares 0 0 0 0
Forfeited shares reissued 0 0 0 0
Value of shares paid-up 2,50,92,910 2,50,92,910 2,50,92,910 2,50,92,910
Reconciliation of number of shares outstanding
[Abstract]
Changes in number of shares outstanding
[Abstract]
Increase in number of shares outstanding
[Abstract]
Number of shares issued in public offering [shares] 0 [shares] 0 [shares] 0 [shares] 0
Number of shares issued as bonus shares [shares] 0 [shares] 0 [shares] 0 [shares] 0
Number of shares issued as rights [shares] 0 [shares] 0 [shares] 0 [shares] 0
Number of shares issued in private
placement arising out of conversion of
[shares] 0 [shares] 0 [shares] 0 [shares] 0
debentures preference shares during
period
Number of shares issued in other private
placement
Number of shares issued as preferential
allotment arising out of conversion of
debentures preference shares during
period
Number of shares issued as other
preferential allotment
Number of shares allotted for
contracts without payment received [shares] 0 [shares] 0 [shares] 0 [shares] 0
in cash
Number of shares issued under scheme of
amalgamation
Number of other issues of shares [shares] 0 [shares] 0 [shares] 0 [shares] 0
Number of shares issued under employee
stock option plan
Number of other issue of shares
arising out of conversion of [shares] 0 [shares] 0 [shares] 0 [shares] 0
securities
Total aggregate number of shares issued
during period
Decrease in number of shares during period
[Abstract]
Number of shares bought back [shares] 0 [shares] 0 [shares] 0 [shares] 0
Other decrease in number of shares [shares] 0 [shares] 0 [shares] 0 [shares] 0
14
Total decrease in number of shares during

period
Total increase (decrease) in number of
shares outstanding
Number of shares outstanding at end of period [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291 [shares] 25,09,291
Reconciliation of value of shares outstanding
[Abstract]
Changes in share capital [Abstract]
Increase in share capital during period
[Abstract]
Amount of public issue during period 0 0 0 0
Amount of bonus issue during period 0 0 0 0
Amount of rights issue during period 0 0 0 0
Amount of private placement issue
arising out of conversion of debentures 0 0 0 0
preference shares during period
Amount of other private placement issue
0 0 0 0
during period
Amount of preferential allotment issue
arising out of conversion of debentures 0 0 0 0
preference shares during period
Amount of other preferential allotment
0 0 0 0
issue during period
Amount of issue allotted for
contracts without payment 0 0 0 0
received in cash during period
Amount of issue under scheme of
0 0 0 0
amalgamation during period
Amount of other issues during period 0 0 0 0
Amount of employee stock option plan
0 0 0 0
issued during period
Amount of other issue arising out of
conversion of securities during 0 0 0 0
period
Total aggregate amount of increase in
0 0 0 0
share capital during period
Decrease in share capital during period
[Abstract]
Decrease in amount of shares bought back 0 0 0 0
Other decrease in amount of shares 0 0 0 0
Total decrease in share capital during
0 0 0 0
period
Total increase (decrease) in share capital 0 0 0 0
Share capital at end of period 2,50,92,910 2,50,92,910 2,50,92,910 2,50,92,910
Shares in company held by holding company or
ultimate holding company or by its subsidiaries
or associates [Abstract]
Shares in company held by holding company [shares] 24,32,104 [shares] 24,32,104 [shares] 24,32,104 [shares] 24,32,104
Shares in company held by ultimate holding
company
Shares in company held by subsidiaries of its
holding company
Shares in company held by subsidiaries of its
ultimate holding company
Shares in company held by associates of its
holding company
Shares in company held by associates of its
ultimate holding company
Total shares in company held by holding company
or ultimate holding company or by its [shares] 24,32,104 [shares] 24,32,104 [shares] 24,32,104 [shares] 24,32,104
subsidiaries or associates
Shares reserved for issue under options
and contracts or commitments for sale of [shares] 0 [shares] 0 [shares] 0 [shares] 0
shares or disinvestment
Amount of shares reserved for issue under options
and contracts or commitments for sale of shares or 0 0 0 0
disinvestment
Aggregate number of fully paid-up shares issued
pursuant to contracts without payment being [shares] 0 [shares] 0 [shares] 0 [shares] 0
received in cash during last five years
Aggregate number of fully paid-up shares
issued by way of bonus shares during last [shares] 0 [shares] 0 [shares] 0 [shares] 0
five years
Aggregate number of shares bought back during
last five years
15
Original paid-up value of forfeited shares 0 0 0 0

Details of application money received for
allotment of securities and due for refund and
interest accrued thereon [Abstract]
Application money received for allotment of
securities and due for refund and interest
accrued thereon [Abstract]
Application money received for
allotment of securities and due for 0 0 0 0
refund, principal
Application money received for
allotment of securities and due for 0 0 0 0
refund, interest accrued
Total application money received for
allotment of securities and due for refund 0 0 0 0
and interest accrued thereon
Number of shares proposed to be issued [shares] 0 [shares] 0 [shares] 0 [shares] 0
Share premium for shares to be allotted 0 0 0 0
16
Disclosure of classes of share capital [Table] ..(2)

Classes of share capital [Axis] Equity shares 1 [Member]
01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of classes of share capital [Abstract]
Disclosure of classes of share capital [LineItems]
Type of share Equity Equity
Number of shares authorised [shares] 45,00,000 [shares] 45,00,000
Value of shares authorised 4,50,00,000 4,50,00,000
Number of shares issued [shares] 25,09,291 [shares] 25,09,291
Value of shares issued 2,50,92,910 2,50,92,910
Number of shares subscribed and fully paid [shares] 25,09,291 [shares] 25,09,291
Value of shares subscribed and fully paid 2,50,92,910 2,50,92,910
Number of shares subscribed but not fully paid [shares] 0 [shares] 0
Value of shares subscribed but not fully paid 0 0
Total number of shares subscribed [shares] 25,09,291 [shares] 25,09,291
Total value of shares subscribed 2,50,92,910 2,50,92,910
Value of shares paid-up [Abstract]
Number of shares paid-up [shares] 25,09,291 [shares] 25,09,291
Value of shares called 2,50,92,910 2,50,92,910
Calls unpaid [Abstract]
Calls unpaid by directors and officers [Abstract]
Calls unpaid by directors 0 0
Calls unpaid by officers 0 0
Total calls unpaid by directors and officers 0 0
Calls unpaid by others 0 0
Total calls unpaid 0 0
Forfeited shares 0 0
Forfeited shares reissued 0 0
Value of shares paid-up 2,50,92,910 2,50,92,910
Par value per share [INR/shares] 10 [INR/shares] 10
Amount per share called in case shares not fully called [INR/shares] 0 [INR/shares] 0
Reconciliation of number of shares outstanding [Abstract]
Changes in number of shares outstanding [Abstract]
Increase in number of shares outstanding [Abstract]
Number of shares issued in public offering [shares] 0 [shares] 0
Number of shares issued as bonus shares [shares] 0 [shares] 0
Number of shares issued as rights [shares] 0 [shares] 0
Number of shares issued in private placement arising out of conversion
[shares] 0 [shares] 0
of debentures preference shares during period
Number of shares issued in other private placement [shares] 0 [shares] 0
Number of shares issued as preferential allotment arising out of
conversion of debentures preference shares during period
Number of shares issued as other preferential allotment [shares] 0 [shares] 0
Number of shares allotted for contracts without payment received in cash [shares] 0 [shares] 0
Number of shares issued under scheme of amalgamation [shares] 0 [shares] 0
Number of other issues of shares [shares] 0 [shares] 0
Number of shares issued under employee stock option plan [shares] 0 [shares] 0
Number of other issue of shares arising out of conversion of securities [shares] 0 [shares] 0
Total aggregate number of shares issued during period [shares] 0 [shares] 0
Decrease in number of shares during period [Abstract]
Number of shares bought back [shares] 0 [shares] 0
Other decrease in number of shares [shares] 0 [shares] 0
Total decrease in number of shares during period [shares] 0 [shares] 0
Total increase (decrease) in number of shares outstanding [shares] 0 [shares] 0
Number of shares outstanding at end of period [shares] 25,09,291 [shares] 25,09,291
Reconciliation of value of shares outstanding [Abstract]
Changes in share capital [Abstract]
Increase in share capital during period [Abstract]
Amount of public issue during period 0 0
Amount of bonus issue during period 0 0
Amount of rights issue during period 0 0
Amount of private placement issue arising out of conversion of
0 0
debentures preference shares during period
Amount of other private placement issue during period 0 0
17
Amount of preferential allotment issue arising out of conversion of

0 0
debentures preference shares during period
Amount of other preferential allotment issue during period 0 0
Amount of issue allotted for contracts without payment received in cash
0 0
during period
Amount of issue under scheme of amalgamation during period 0 0
Amount of other issues during period 0 0
Amount of employee stock option plan issued during period 0 0
Amount of other issue arising out of conversion of securities during period 0 0
Total aggregate amount of increase in share capital during period 0 0
Decrease in share capital during period [Abstract]
Decrease in amount of shares bought back 0 0
Other decrease in amount of shares 0 0
Total decrease in share capital during period 0 0
Total increase (decrease) in share capital 0 0
Share capital at end of period 2,50,92,910 2,50,92,910
Shares in company held by holding company or ultimate holding company or by its
subsidiaries or associates [Abstract]
Shares in company held by holding company [shares] 24,32,104 [shares] 24,32,104
Shares in company held by ultimate holding company [shares] 0 [shares] 0
Shares in company held by subsidiaries of its holding company [shares] 0 [shares] 0
Shares in company held by subsidiaries of its ultimate holding company [shares] 0 [shares] 0
Shares in company held by associates of its holding company [shares] 0 [shares] 0
Shares in company held by associates of its ultimate holding company [shares] 0 [shares] 0
Total shares in company held by holding company or ultimate holding company
[shares] 24,32,104 [shares] 24,32,104
or by its subsidiaries or associates
Shares reserved for issue under options and contracts or commitments for sale of
shares or disinvestment
Amount of shares reserved for issue under options and contracts or commitments
0 0
for sale of shares or disinvestment
Aggregate number of fully paid-up shares issued pursuant to contracts
without payment being received in cash during last five years
Aggregate number of fully paid-up shares issued by way of bonus shares during last
five years
Aggregate number of shares bought back during last five years [shares] 0 [shares] 0
Original paid-up value of forfeited shares 0 0
Details of application money received for allotment of securities and due for
refund and interest accrued thereon [Abstract]
Application money received for allotment of securities and due for refund and
interest accrued thereon [Abstract]
Application money received for allotment of securities and due for refund,
0 0
principal
Application money received for allotment of securities and due for refund,
0 0
interest accrued
Total application money received for allotment of securities and due for
0 0
refund and interest accrued thereon
Number of shares proposed to be issued [shares] 0 [shares] 0
Share premium for shares to be allotted 0 0

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of notes on share capital explanatory [TextBlock] [See below]
Whether there are any shareholders holding more than five per cent
Yes Yes
shares in company
Whether money raised from public offering during year No
18
Disclosure of notes on share capital explanatory [Text Block]
Share capital
As at As at
31 March 2021 31 March 2020
Authorized
4,500,000 (previous year: 4,500,000) equity shares of Rs. 10 each 45,000,000 45,000,000
45,000,000 45,000,000
Issued, subscribed and paid-up
2,509,291 (previous year: 2,509,291) equity shares of Rs. 10 each, fully paid up 25,092,910 25,092,910
25,092,910 25,092,910
a) Reconciliation of shares outstanding at the beginning and at the end of the year:
As at As at
31 March 2021 31 March 2020
Number Amount Amount
Equity shares
At the commencement of the year 25,09,291 2,50,92,910 25,09,291 2,50,92,910
Issued during the year - - - -
At the end of the year 25,09,291 2,50,92,910 25,09,291 2,50,92,910
b) Rights, preferences and restrictions attached to equity shares:
The Company has a single class of equity shares having a par value of Rs. 10 per share. Accordingly, all equity shares rank equally with
regard to dividends and share in the Companys residual assets. The equity shareholders are entitled to receive dividend as declared from time
to time. The dividend proposed by the Board of Directors, if any, is subject to shareholders approval in the ensuing Annual General Meeting.
The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share in the paid-up equity capital of the
Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.
19
Failure to pay any amount called up on shares may lead to forfeiture of the shares. On winding up of the Company, the holders of equity
shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to
the number of equity shares held.
c) Shares held by holding company
As at As at
31 March 2021 31 March 2020
Number % age Number % age
Equity share of Rs 10 each fully paid-up held by
MedGenome Inc. 24,32,104 96.92% 24,32,104 96.92%
d) Particulars of shareholders holding more than 5% shares of a class of shares
As at As at
31 March 2021 31 March 2020
Number % age Number % age
Equity share of Rs 10 each fully paid-up held by
MedGenome Inc. 24,32,104 96.92% 24,32,104 96.92%
e) There are no bonus shares issued, shares issued for consideration other than cash and shares bought back from the incorporation of the
Company till the reporting date.
20
[200200] Notes - Reserves and surplus
Statement of changes in reserves [Table] ..(1)

Components of reserves [Axis] Reserves [Member] Capital reserves [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Statement of changes in reserves [Abstract]
Statement of changes in reserves [LineItems]
Changes in reserves [Abstract]
Additions to reserves [Abstract]
Profit (loss) for period 10,49,58,995 -48,03,77,846 0 0
Other additions to reserves 6,88,55,283 0 (A) 7,28,91,642 0
Total additions to reserves 17,38,14,278 -48,03,77,846 7,28,91,642 0
Total changes in reserves 17,38,14,278 -48,03,77,846 7,28,91,642 0
Reserves at end of period -19,38,98,881 -36,77,13,159 7,28,91,642 0
(A) Expense during the year

Capital reserves
Components of reserves [Axis] Securities premium account [Member]
[Member]
01/04/2020 01/04/2019
31/03/2019 to to 31/03/2019
31/03/2021 31/03/2020
Profit (loss) for period 0 0
Total changes in reserves 0 0
Reserves at end of period 0 57,55,17,334 57,55,17,334 57,55,17,334

Components of reserves [Axis] Surplus [Member]
01/04/2020 01/04/2019
to to 31/03/2019
31/03/2021 31/03/2020
Profit (loss) for period 10,49,58,995 -48,03,77,846
Other additions to reserves (A) -40,36,359 0
Total additions to reserves 10,09,22,636 -48,03,77,846
Total changes in reserves 10,09,22,636 -48,03,77,846
Reserves at end of period -84,23,07,857 -94,32,30,493 -46,28,52,647
(A) Amount transferred from Minority interest

01/04/2020
to
31/03/2021
Disclosure of notes on reserves explanatory [TextBlock] [See below]
21
Disclosure of notes on reserves explanatory [Text Block]

Reserves and surplus
As at As at
31 March 2021 31 March 2020
Capital reserve*
At the commencement of the year - -
Expense during the year 7,28,91,642 -
7,28,91,642 -
Deficit in the statement of profit and loss
At the commencement of the year (94,32,30,493) (46,28,52,647)
Add: Profit / (loss) for the year 10,49,58,995 (48,03,77,846)
Add: Amount transferred from Minority interest
(40,36,359)
(84,23,07,857) (94,32,30,493)
Securities premium account
At the commencement of the year 57,55,17,334 57,55,17,334
57,55,17,334 57,55,17,334
(19,38,98,881) (36,77,13,159)
*Capital contribution received from the Medgenome Inc., ultimate holding company of the Company for employee stock option scheme
22
[200300] Notes - Borrowings
Details of bonds or debentures [Table] ..(1)

Details of bonds or debentures [Axis] 1
01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Borrowings notes [Abstract]
Details of bonds or debentures [Abstract]
Details of bonds or debentures [LineItems]
Whether bonds or debentures Debenture Debenture
Nature of bond or debenture Fully convertible Fully convertible
Holder of bond or debenture Others Others
Rate of interest 0.0001% 0.0001%
Textual information Textual information
Particulars of redemption or conversion (4) [See below] (5) [See below]
Nominal value per bond or debenture [pure] 1,000 [pure] 1,000
Number of bonds or debentures [pure] 4,14,480 [pure] 5,84,480
Amount of bonds or debentures issued during period 4,14,80,000 58,44,80,000
Number of allottees to whom bonds or debentures were issued [pure] 6 [pure] 7
Classification of borrowings [Table] ..(1)

Classification based on time period [Axis] Long-term [Member]
Classification of borrowings [Axis] Borrowings [Member]
Subclassification of borrowings [Axis] Secured borrowings [Member] Unsecured borrowings [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Details of borrowings [Abstract]
Details of borrowings [LineItems]
Borrowings 6,53,69,958 12,66,31,273 41,44,80,000 58,44,80,000

Classification of borrowings [Axis] Bonds/debentures [Member] Debentures [Member]
Subclassification of borrowings [Axis] Unsecured borrowings [Member] Unsecured borrowings [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Borrowings 41,44,80,000 58,44,80,000 41,44,80,000 58,44,80,000

Fully convertible debentures others
Classification of borrowings [Axis] Term loans [Member]
[Member]
Subclassification of borrowings [Axis] Unsecured borrowings [Member] Secured borrowings [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Borrowings (A) 41,44,80,000 58,44,80,000 6,32,69,958 12,45,31,273
Footnotes
(A) ** Represents 0.0001% Compulsory Convertible Debentures (CCD's) issued by the Company to following holders :
ParticularsNumber of debentures issuedAmount HDFC Assest Management Company Limited49,896 4,98,96,000 Housing
Development Finance Corporation Limited1,99,584 19,95,84,000 Lakshmi Narayanan32,500 3,25,00,000 Pratithi Investment
Trust32,500 3,25,00,000 Yogesh Agrawal50,000 5,00,00,000 Rajesh Agrawal50,000 5,00,00,000 4,14,48041,44,80,000 The term of
CCD is 10 year from the date of issuance. CCD carries an interest rate of 0.0001% per annum. Each CCD will shall be convertible
into equity share at any time during 10 year from the date of their issuance, with written permission from the Holding Company.
Holder of CCD shall not have any voting rights. The CCD will be compulsorily convertible into equity share at the end of 10 year
from the date of their issuance. During the year the compulsory convertible debentures (CCD's) of Avezo Advisors Private Limited
was converted into optionally convertible debentures (OCD's) and were redeemed.
23

Rupee term loans from banks
Classification of borrowings [Axis] Term loans from banks [Member]
[Member]
Subclassification of borrowings [Axis] Secured borrowings [Member] Secured borrowings [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Borrowings 6,32,69,958 12,45,31,273 (A) 6,32,69,958 (B) 12,45,31,273
Footnotes
(A) Term loan* Includes loan from HDFC Bank Limited towards purchase of laboratory equipments availed in various tranches. The
loan is repayable in 54 to 60 equal monthly installments and is secured against the underlying laboratory equipments, book debts and
fixed deposit. The loan carries an interest rate of 3 month LIBOR plus 5% per annum to 1 year LIBOR plus 4.75% per annum. The
current maturities of long term borrowing has been shown under other current liabilities.
(B) Term loan* Includes loan from HDFC Bank Limited towards purchase of laboratory equipments availed in various tranches. The
loan is repayable in 54 to 60 equal monthly installments and is secured against the underlying laboratory equipments, book debts and
fixed deposit. The loan carries an interest rate of 3 month LIBOR plus 5% per annum to 1 year LIBOR plus 4.75% per annum. The
current maturities of long term borrowing has been shown under other current liabilities.

Loans and advances from related Loans and advances from directors
Classification of borrowings [Axis]
parties [Member] [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Borrowings 21,00,000 21,00,000 (A) 21,00,000 (B) 21,00,000
Footnotes
(A) Loan from director** **The loan is taken from director Mr. Padnambha Shenoy on 3rd September 2019 . Loan is repayable on
demand and it is non interest bearing ..
(B) Loan from director** **The loan is taken from director Mr. Padnambha Shenoy on 3rd September 2019 . Loan is repayable on
demand and it is non interest bearing ..

Classification based on time period [Axis] Short-term [Member]
Classification of borrowings [Axis] Borrowings [Member] Other loans and advances [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Borrowings 65,28,151 47,10,563 65,28,151 47,10,563

Other loans and advances, others
Classification of borrowings [Axis]
[Member]
Subclassification of borrowings [Axis] Secured borrowings [Member]
31/03/2021 31/03/2020
Borrowings (A) 65,28,151 (B) 47,10,563
Footnotes
(A) Overdraft facility with bank The Company has obtained overdraft facility from the HDFC bank. The loan is secured against book
debt and carries interest rate of 12.5% per annum.
(B) Overdraft facility with bank The Company has obtained overdraft facility from the HDFC bank. The loan is secured against book
debt and carries interest rate of 12.5% per annum.
24

01/04/2020
to
31/03/2021
Disclosure of notes on borrowings explanatory [TextBlock] [See below]
Particulars of redemption or conversion

The term of CCD is 10 year from the date of issuance. CCD carries an interest rate of 0.0001% per annum. Each CCD will shall be
convertible into equity share at any time during 10 year from the date of their issuance, with written permission from the Holding Company.
Holder of CCD shall not have any voting rights. The CCD will be compulsorily convertible into equity share at the end of 10 year from the
date of their issuance. During the year the compulsory convertible debentures (CCD's) of Avezo Advisors Private Limited was converted into
optionally convertible debentures (OCD's) and were redeemed.
Particulars of redemption or conversion

25
Disclosure of notes on borrowings explanatory [Text Block]

Long-term borrowings
As at As at
31 March 2021 31 March 2020
Secured loan
Term loan* 6,32,69,958 12,45,31,273
Loan from director** (Refer note 3.28) 21,00,000 21,00,000
6,53,69,958 12,66,31,273
Unsecured loan
Compulsory convertible debentures*** 41,44,80,000 58,44,80,000
41,44,80,000 58,44,80,000
Includes loan from HDFC Bank Limited towards purchase of laboratory equipments availed in various tranches. The loan is repayable in 54
to 60 equal monthly installments and is secured against the underlying laboratory equipments, book debts and fixed deposit. The loan carries
an interest rate of 3 month LIBOR plus 5% per annum to 1 year LIBOR plus 4.75% per annum. The current maturities of long term
borrowing has been shown under other current liabilities.
**The loan is taken from director Mr. Padnambha Shenoy on 3rd September 2019 . Loan is repayable on demand and it is non interest
bearing ..
*** Represents 0.0001% Compulsory Convertible Debentures (CCD's) issued by the Company to following holders :
Particulars Number of debentures issued Amount
HDFC Assest Management Company Limited 49,896 49,896,000
Housing Development Finance Corporation Limited 199,584 199,584,000
Lakshmi Narayanan 32,500 32,500,000
26
Pratithi Investment Trust 32,500 32,500,000
Yogesh Agrawal 50,000 50,000,000
Rajesh Agrawal 50,000 50,000,000
414,480 414,480,000
Short-term borrowings
As at
As at
31 March
31 March 2021
2020
Secured
Overdraft facility with bank 65,28,151

47,10,563
Loan from holding company*

-
65,28,151 47,10,563
The Company has obtained overdraft facility from the HDFC bank. The loan is secured against book debt
and carries interest rate of 12.5% per annum.
27
[201000] Notes - Tangible assets
Disclosure of tangible assets [Table] ..(1)

Classes of tangible assets [Axis] Company total tangible assets [Member]
Sub classes of tangible assets [Axis] Owned and leased assets [Member]
Carrying amount accumulated depreciation and Gross carrying amount Accumulated depreciation and
Carrying amount [Member]
gross carrying amount [Axis] [Member] impairment [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of tangible assets [Abstract]
Disclosure of tangible assets
[LineItems]
Reconciliation of changes in
tangible assets [Abstract]
Changes in tangible assets
[Abstract]
Additions other than through
business combinations tangible 9,99,88,760 8,31,46,251 9,99,88,760 8,31,46,251
assets
Depreciation tangible assets -15,59,11,731 -18,40,68,374 15,59,11,731 18,40,68,374
Impairment loss
recognised in profit or 0 0 0 0
loss tangible assets
Reversal of impairment loss
recognised in profit or loss 0 0 0 0
tangible assets
Disposals tangible assets
[Abstract]
Disposals tangible assets,
0 34,51,664 0 2,34,40,749 0 1,99,89,085
others
Total disposals tangible
0 34,51,664 0 2,34,40,749 0 1,99,89,085
assets
Other adjustments tangible
assets [Abstract]
0 0 0 0
assets, others
Total other adjustments
0 0 0 0
tangible assets
Total changes in tangible
-5,59,22,971 -10,43,73,787 9,99,88,760 5,97,05,502 15,59,11,731 16,40,79,289
assets
Tangible assets at end of period (A) 26,04,05,746 (B) 31,63,28,715 107,41,09,163 97,41,20,403 81,37,03,417 65,77,91,688
Footnotes
(A) Rs. 2 has been adjusted to match the total in table.
(B) Rs. 2 has been adjusted to match the total in table.
28

Classes of tangible assets [Axis] Company total tangible assets [Member]
Sub classes of tangible assets [Axis] Assets held under lease [Member] Owned assets [Member]
Accumulated
Gross
Carrying Gross carrying depreciation
Carrying amount accumulated depreciation and carrying
amount amount and Carrying amount [Member]
gross carrying amount [Axis] amount
[Member] [Member] impairment
[Member]
[Member]
01/04/2019 01/04/2019 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2020 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 5,42,91,050 5,42,91,050 9,99,88,760 2,88,55,201 9,99,88,760
assets
Depreciation tangible assets -13,37,67,550 13,37,67,550 -15,59,11,731 -5,03,00,824
Impairment loss
tangible assets
[Abstract]
5,85,980 28,15,831 22,29,851 0 28,65,684 0
others
5,85,980 28,15,831 22,29,851 0 28,65,684 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-8,00,62,480 5,14,75,219 13,15,37,699 -5,59,22,971 -2,43,11,307 9,99,88,760
assets
Tangible assets at end of period 21,94,55,428 69,05,19,718 47,10,64,290 26,04,05,746 9,68,73,287 107,41,09,163
29

Classes of tangible assets [Axis] Company total tangible assets [Member] Furniture and fixtures [Member]
Sub classes of tangible assets [Axis] Owned assets [Member] Owned and leased assets [Member]
Gross
Gross carrying
Carrying amount accumulated depreciation and Accumulated depreciation and carrying
amount Carrying amount [Member]
gross carrying amount [Axis] impairment [Member] amount
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 2,88,55,201 72,000 50,500 72,000
assets
Depreciation tangible assets 15,59,11,731 5,03,00,824 -97,207 -2,46,969
Impairment loss
tangible assets
[Abstract]
2,06,24,918 0 1,77,59,234 0 0 0
others
2,06,24,918 0 1,77,59,234 0 0 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
82,30,283 15,59,11,731 3,25,41,590 -25,207 -1,96,469 72,000
assets
Tangible assets at end of period 28,36,00,685 81,37,03,417 18,67,27,398 1,83,470 2,08,677 14,09,831
30

Classes of tangible assets [Axis] Furniture and fixtures [Member]
Sub classes of tangible assets [Axis] Owned and leased assets [Member] Owned assets [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 50,500 72,000 50,500 72,000
assets
Depreciation tangible assets 97,207 2,46,969 -97,207 -2,46,969
Impairment loss
tangible assets
[Abstract]
4,07,238 0 4,07,238 0 0 0
others
4,07,238 0 4,07,238 0 0 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-3,56,738 97,207 -1,60,269 -25,207 -1,96,469 72,000
assets
Tangible assets at end of period 13,37,831 12,26,361 11,29,154 1,83,470 2,08,677 14,09,831
31

Classes of tangible assets [Axis] Furniture and fixtures [Member] Vehicles [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 50,500 0 0 0
assets
Depreciation tangible assets 97,207 2,46,969 -1,64,749 -1,83,333
Impairment loss
tangible assets
[Abstract]
4,07,238 0 4,07,238 0 3,48,082 0
others
4,07,238 0 4,07,238 0 3,48,082 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-3,56,738 97,207 -1,60,269 -1,64,749 -5,31,415 0
assets
Tangible assets at end of period 13,37,831 12,26,361 11,29,154 0 1,64,749 5,50,000
32

Classes of tangible assets [Axis] Vehicles [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 0 0 0 0
assets
Depreciation tangible assets 1,64,749 1,83,333 -1,64,749 -1,83,333
Impairment loss
tangible assets
[Abstract]
5,50,000 0 2,01,918 0 3,48,082 0
others
5,50,000 0 2,01,918 0 3,48,082 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-5,50,000 1,64,749 -18,585 -1,64,749 -5,31,415 0
assets
Tangible assets at end of period 5,50,000 5,50,000 3,85,251 0 1,64,749 5,50,000
33

Classes of tangible assets [Axis] Vehicles [Member] Office equipment [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 0 13,16,922 19,02,350 13,16,922
assets
Impairment loss
tangible assets
[Abstract]
5,50,000 0 2,01,918 0 4,84,129 0
others
5,50,000 0 2,01,918 0 4,84,129 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-5,50,000 1,64,749 -18,585 -14,64,852 -14,58,307 13,16,922
assets
Tangible assets at end of period 5,50,000 5,50,000 3,85,251 46,65,280 61,30,132 1,48,68,226
34

Classes of tangible assets [Axis] Office equipment [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 19,02,350 13,16,922 19,02,350 13,16,922
assets
Impairment loss
tangible assets
[Abstract]
24,04,221 0 19,20,092 0 4,84,129 0
others
24,04,221 0 19,20,092 0 4,84,129 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-5,01,871 27,81,774 9,56,436 -14,64,852 -14,58,307 13,16,922
assets
Tangible assets at end of period 1,35,51,304 1,02,02,946 74,21,172 46,65,280 61,30,132 1,48,68,226
35

Classes of tangible assets [Axis] Office equipment [Member] Computer equipments [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 19,02,350 1,01,18,769 94,07,551 1,01,18,769
assets
Depreciation tangible assets 27,81,774 28,76,528 -1,95,46,569 -2,01,52,778
Impairment loss
tangible assets
[Abstract]
24,04,221 0 19,20,092 0 7,42,128 0
others
24,04,221 0 19,20,092 0 7,42,128 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-5,01,871 27,81,774 9,56,436 -94,27,800 -1,14,87,355 1,01,18,769
assets
Tangible assets at end of period 1,35,51,304 1,02,02,946 74,21,172 3,35,44,360 4,29,72,160 14,11,57,011
36

Classes of tangible assets [Axis] Computer equipments [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 94,07,551 1,01,18,769 94,07,551 1,01,18,769
assets
Depreciation tangible assets 1,95,46,569 2,01,52,778 -1,95,46,569 -2,01,52,778
Impairment loss
tangible assets
[Abstract]
37,12,257 0 29,70,129 0 7,42,128 0
others
37,12,257 0 29,70,129 0 7,42,128 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
56,95,294 1,95,46,569 1,71,82,649 -94,27,800 -1,14,87,355 1,01,18,769
assets
37

Classes of tangible assets [Axis] Computer equipments [Member] Leasehold improvements [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 94,07,551 49,13,284 1,74,94,800 49,13,284
assets
Impairment loss
tangible assets
[Abstract]
37,12,257 0 29,70,129 0 12,91,345 0
others
37,12,257 0 29,70,129 0 12,91,345 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
56,95,294 1,95,46,569 1,71,82,649 -1,53,49,513 -1,06,37,761 49,13,284
assets
38

Classes of tangible assets [Axis] Leasehold improvements [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 1,74,94,800 49,13,284 1,74,94,800 49,13,284
assets
Impairment loss
tangible assets
[Abstract]
1,35,51,202 0 1,22,59,857 0 12,91,345 0
others
1,35,51,202 0 1,22,59,857 0 12,91,345 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
39,43,598 2,02,62,797 1,45,81,359 -1,53,49,513 -1,06,37,761 49,13,284
assets
39

Classes of tangible assets [Axis] Leasehold improvements [Member] Other tangible assets [Member]
Gross
Gross carrying
[Member]
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021
[LineItems]
[Abstract]
business combinations tangible 1,74,94,800 8,35,67,785 5,42,91,050 8,35,67,785
assets
Impairment loss
tangible assets
[Abstract]
1,35,51,202 0 1,22,59,857 0 5,85,980 0
others
1,35,51,202 0 1,22,59,857 0 5,85,980 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
39,43,598 2,02,62,797 1,45,81,359 -2,94,90,850 -8,00,62,480 8,35,67,785
assets
40

Classes of tangible assets [Axis] Other tangible assets [Member]
Sub classes of tangible assets [Axis] Owned and leased assets [Member] Assets held under lease [Member]
Accumulated
Gross carrying Carrying Gross carrying depreciation
Carrying amount accumulated depreciation and Accumulated depreciation and
amount amount amount and
gross carrying amount [Axis] impairment [Member]
[Member] [Member] [Member] impairment
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2019 01/04/2019 01/04/2019
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2020 31/03/2020 31/03/2020
[LineItems]
[Abstract]
business combinations tangible 5,42,91,050 5,42,91,050 5,42,91,050
assets
Depreciation tangible assets 11,30,58,635 13,37,67,550 -13,37,67,550 13,37,67,550
Impairment loss
tangible assets
[Abstract]
28,15,831 0 22,29,851 5,85,980 28,15,831 22,29,851
others
28,15,831 0 22,29,851 5,85,980 28,15,831 22,29,851
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
5,14,75,219 11,30,58,635 13,15,37,699 -8,00,62,480 5,14,75,219 13,15,37,699
assets
41

Classes of tangible assets [Axis] Other tangible assets [Member] Other tangible assets, others [Member]
Accumulated
Gross
Carrying Gross carrying depreciation
Carrying amount accumulated depreciation and carrying
amount amount and Carrying amount [Member]
gross carrying amount [Axis] amount
[Member] [Member] impairment
[Member]
[Member]
01/04/2020 01/04/2020 01/04/2020 01/04/2020 01/04/2019 01/04/2020
to to to to to to
31/03/2021 31/03/2021 31/03/2021 31/03/2021 31/03/2020 31/03/2021
[LineItems]
Nature of other tangible assets 0 0 0
[Abstract]
business combinations tangible 8,35,67,785 8,35,67,785 8,35,67,785 5,42,91,050 8,35,67,785
assets
Depreciation tangible assets -11,30,58,635 11,30,58,635 -11,30,58,635 -13,37,67,550
Impairment loss
tangible assets
[Abstract]
0 0 0 0 5,85,980 0
others
0 0 0 0 5,85,980 0
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
-2,94,90,850 8,35,67,785 11,30,58,635 -2,94,90,850 -8,00,62,480 8,35,67,785
assets
42

Classes of tangible assets [Axis] Other tangible assets, others [Member]
Sub classes of tangible assets [Axis] Owned and leased assets [Member] Assets held under lease [Member]
Accumulated
Gross carrying Carrying Gross carrying depreciation
Carrying amount accumulated depreciation and Accumulated depreciation and
amount amount amount and
gross carrying amount [Axis] impairment [Member]
[Member] [Member] [Member] impairment
[Member]
01/04/2019 01/04/2020 01/04/2019 01/04/2019 01/04/2019 01/04/2019
to to to to to to
31/03/2020 31/03/2021 31/03/2020 31/03/2020 31/03/2020 31/03/2020
[LineItems]
Nature of other tangible assets 0 0 0 0 0 0
[Abstract]
business combinations tangible 5,42,91,050 5,42,91,050 5,42,91,050
assets
Depreciation tangible assets 11,30,58,635 13,37,67,550 -13,37,67,550 13,37,67,550
Impairment loss
tangible assets
[Abstract]
28,15,831 0 22,29,851 5,85,980 28,15,831 22,29,851
others
28,15,831 0 22,29,851 5,85,980 28,15,831 22,29,851
assets
assets [Abstract]
0 0 0 0
assets, others
0 0 0 0
tangible assets
5,14,75,219 11,30,58,635 13,15,37,699 -8,00,62,480 5,14,75,219 13,15,37,699
assets
43

Sub classes of tangible assets [Axis] Owned assets [Member]
Accumulated
Carrying amount Gross carrying depreciation and
Carrying amount accumulated depreciation and gross carrying amount [Axis]
[Member] amount [Member] impairment
[Member]
01/04/2020 01/04/2020 01/04/2020
to to to
31/03/2021 31/03/2021 31/03/2021
Disclosure of tangible assets [LineItems]
Nature of other tangible assets 0 0 0
Reconciliation of changes in tangible assets [Abstract]
Changes in tangible assets [Abstract]
Additions other than through business combinations tangible
8,35,67,785 8,35,67,785
assets
Depreciation tangible assets -11,30,58,635 11,30,58,635
Impairment loss recognised in profit or loss tangible assets 0 0
Reversal of impairment loss recognised in profit or loss
0 0
tangible assets
Disposals tangible assets [Abstract]
Disposals tangible assets, others 0 0 0
Total disposals tangible assets 0 0 0
Other adjustments tangible assets [Abstract]
Other adjustments tangible assets, others 0 0
Total other adjustments tangible assets 0 0
Total changes in tangible assets -2,94,90,850 8,35,67,785 11,30,58,635
Tangible assets at end of period 18,99,64,578 77,40,87,503 58,41,22,925
Disclosure of additional information tangible assets [Table] ..(1)

Company total tangible assets
Classes of tangible assets [Axis] Furniture and fixtures [Member]
[Member]
Owned and leased assets Owned and leased assets
[Member] [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of additional information
tangible assets [LineItems]
straight line straight line
Depreciation method tangible assets - - - -
method method
Useful lives or depreciation rates
NA NA NA NA 3 years 3.00
tangible assets

Classes of tangible assets [Axis] Vehicles [Member] Office equipment [Member]
[Member] [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
Depreciation method tangible assets - -
method method
- -

NA NA 3 Years 3.00 NA NA
tangible assets
44

Classes of tangible assets [Axis] Office equipment [Member] Computer equipments [Member]
Owned and leased assets
Sub classes of tangible assets [Axis] Owned assets [Member] Owned assets [Member]
[Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
straight line straight line straight line straight line
Depreciation method tangible assets method method
- -
method method
3-5 Years 3-5 yrs NA NA 3-6 Years 3 -6 yrs
tangible assets

Other tangible assets
Classes of tangible assets [Axis] Leasehold improvements [Member]
[Member]
[Member] [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
Depreciation method tangible assets - -
method method
- -

NA NA 5 Years 5.00 NA NA
tangible assets

Assets held under Owned assets
Sub classes of tangible assets [Axis] Owned and leased assets [Member]
lease [Member] [Member]
01/04/2020 01/04/2019 01/04/2019 01/04/2020
to to to to
31/03/2021 31/03/2020 31/03/2020 31/03/2021
Disclosure of additional information tangible assets
[Abstract]
Disclosure of additional information tangible assets
[LineItems]
Depreciation method tangible assets - - straight line method straight line method
Useful lives or depreciation rates tangible assets NA NA 5 yrs 5 years

01/04/2020
to
31/03/2021
Disclosure of notes on tangible assets explanatory [TextBlock] [See below]
45
Disclosure of notes on tangible assets explanatory [Text Block]
Accumulated
depreciation
Particulars Gross block Net block
and
amortization
As at As at As at As at
As at Charge for
Additions Deletions 31 March 1 April Deletions 31 March 31 March
1 April 2020 the year
2021 2020 2021 2021
Plant and
equipment
Laboratory
equipment 69,05,19,718 8,35,67,785 - 77,40,87,503 47,10,64,290 11,30,58,635 - 58,41,22,925 18,99,
Computer and
hardware 13,10,38,242 1,01,18,769 - 14,11,57,011 8,80,66,082 1,95,46,569 - 10,76,12,652 3,35,44,35
Office
equipments 1,35,51,304 13,16,922 - 1,48,68,226 74,21,172 27,81,774 - 1,02,02,948 46,65,278
Vehicles
5,50,000 - - 5,50,000 3,85,251 1,64,749 - 5,50,000 -
Furniture and
fixtures 13,37,831 72,000 - 14,09,831 11,29,154 97,204 - 12,26,358 1,83,473
Leasehold
improvements 13,71,23,308 49,13,284 - 14,20,36,592 8,97,25,737 2,02,62,797 - 10,99,88,534 3,20,48,05
Total plant
and
97,41,20,403 9,99,88,760 - 1,07,41,09,163 65,77,91,686 15,59,11,728 - 81,37,03,417 26,04,05,7
equipment
Intangible
assets
Software
3,59,08,352 - - 3,59,08,352 2,96,46,583 59,05,098 - 3,55,51,681 3,56,671
Total
intangible
3,59,08,352 - - 3,59,08,352 2,96,46,583 59,05,098 - 3,55,51,681 3,56,671
assets
Total
1,01,00,28,755 9,99,88,760 - 1,11,00,17,515 68,74,38,269 16,18,16,826 - 84,92,55,098 26,07,62,4
46
Accumulated
depreciation
and
amortization
As at As at As at As at
As at Charge for
Additions Deletions 31 March 1 April Deletions 31 March 31 March
1 April 2019 the year
2020 2019 2020 2020
Plant and
equipment
Laboratory
equipment 63,90,44,499 5,42,91,050 28,15,831 69,05,19,718 33,95,26,591 13,37,67,550 22,29,851 47,10,64,290 21,94,55,4
Computer and
hardware 12,53,42,948 94,07,551 37,12,257 13,10,38,242 7,08,83,433 2,01,52,778 29,70,129 8,80,66,082 4,29,72,16
Office
equipment 1,40,53,175 19,02,350 24,04,221 1,35,51,304 64,64,736 28,76,528 19,20,092 74,21,172 61,30,132
Vehicles
11,00,000 - 5,50,000 5,50,000 4,03,836 1,83,333 2,01,918 3,85,251 1,64,749
Furniture and
fixtures 16,94,569 50,500 4,07,238 13,37,831 12,89,423 2,46,969 4,07,238 11,29,154 2,08,677
Leasehold
improvements 13,31,79,710 1,74,94,800 1,35,51,202 13,71,23,308 7,51,44,380 2,68,41,216 1,22,59,859 8,97,25,737 4,73,97,55
Total plant
and
91,44,14,901 8,31,46,251 2,34,40,749 97,41,20,403 49,37,12,399 18,40,68,374 1,99,89,087 65,77,91,686 31,63,28,7
equipment
Intangible
assets
Software
3,53,16,354 6,85,111 93,113 3,59,08,352 2,34,61,254 62,78,442 93,113 2,96,46,583 62,61,769
Total
intangible
3,53,16,354 6,85,111 93,113 3,59,08,352 2,34,61,254 62,78,442 93,113 2,96,46,583 62,61,769
assets
Total
94,97,31,255 8,38,31,362 2,35,33,862 1,01,00,28,755 51,71,73,653 19,03,46,816 2,00,82,200 68,74,38,269 32,25,90,4
47
[201100] Notes - Intangible assets
Disclosure of intangible assets [Table] ..(1)

Classes of intangible assets [Axis] Company total intangible assets [Member]
Sub classes of intangible assets [Axis] Internally generated and other than internally generated intangible assets [Member]
Carrying amount accumulated amortization and Gross carrying amount Accumulated amortization and
impairment and gross carrying amount [Axis] [Member] impairment [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of intangible assets [Abstract]
Disclosure of intangible assets
[LineItems]
intangible assets [Abstract]
Changes in intangible assets
[Abstract]
Additions to intangible assets
[Abstract]
business combinations 0 6,85,111 0 6,85,111
intangible assets
Total additions to
0 6,85,111 0 6,85,111
intangible assets
Amortization intangible assets -59,05,098 -62,78,442 59,05,098 62,78,442
Impairment loss
loss intangible assets
intangible assets
Disposals intangible assets
[Abstract]
Disposals intangible
0 0 0 93,113 0 93,113
assets, others
Total disposals intangible
0 0 0 93,113 0 93,113
assets
Other adjustments intangible
assets [Abstract]
Other adjustments
0 0 0 0
intangible assets, others
0 0 0 0
intangible assets
Total changes in intangible
-59,05,098 -55,93,331 0 5,91,998 59,05,098 61,85,329
assets
Intangible assets at end of period 3,56,671 62,61,769 3,59,08,352 3,59,08,352 3,55,51,681 2,96,46,583
48

Classes of intangible assets [Axis] Company total intangible assets [Member]
Intangible assets other than internally
Sub classes of intangible assets [Axis] Internally generated intangible assets [Member]
generated [Member]
Accumulated Accumulated
Carrying Gross carrying amortization Carrying Gross carrying amortization
Carrying amount accumulated amortization and
amount amount and amount amount and
impairment and gross carrying amount [Axis]
[Member] [Member] impairment [Member] [Member] impairment
[Member] [Member]
01/04/2020 01/04/2020 01/04/2020 01/04/2019 01/04/2019 01/04/2019
to to to to to to
31/03/2021 31/03/2021 31/03/2021 31/03/2020 31/03/2020 31/03/2020
[LineItems]
[Abstract]
[Abstract]
business combinations 0 0 6,85,111 6,85,111
intangible assets
Total additions to
0 0 6,85,111 6,85,111
intangible assets
Amortization intangible assets -59,05,098 59,05,098 -62,78,442 62,78,442
Impairment loss
intangible assets
[Abstract]
0 0 0 0 93,113 93,113
assets, others
0 0 0 0 93,113 93,113
assets
assets [Abstract]
Other adjustments
0 0 0 0
0 0 0 0
intangible assets
-59,05,098 0 59,05,098 -55,93,331 5,91,998 61,85,329
assets
Intangible assets at end of period 3,56,671 3,59,08,352 3,55,51,681 62,61,769 3,59,08,352 2,96,46,583
49

Classes of intangible assets [Axis] Other intangible assets [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
[LineItems]
[Abstract]
[Abstract]
intangible assets
Total additions to
0 6,85,111 0 6,85,111
intangible assets
Impairment loss
intangible assets
[Abstract]
0 0 0 93,113 0 93,113
assets, others
0 0 0 93,113 0 93,113
assets
assets [Abstract]
Other adjustments
0 0 0 0
0 0 0 0
intangible assets
-59,05,098 -55,93,331 0 5,91,998 59,05,098 61,85,329
assets
50

Classes of intangible assets [Axis] Other intangible assets [Member]
generated [Member]
[Member] [Member]
01/04/2020 01/04/2020 01/04/2020 01/04/2019 01/04/2019 01/04/2019
to to to to to to
31/03/2021 31/03/2021 31/03/2021 31/03/2020 31/03/2020 31/03/2020
[LineItems]
[Abstract]
[Abstract]
intangible assets
Total additions to
0 0 6,85,111 6,85,111
intangible assets
Impairment loss
intangible assets
[Abstract]
0 0 0 0 93,113 93,113
assets, others
0 0 0 0 93,113 93,113
assets
assets [Abstract]
Other adjustments
0 0 0 0
0 0 0 0
intangible assets
-59,05,098 0 59,05,098 -55,93,331 5,91,998 61,85,329
assets
51

Classes of intangible assets [Axis] Other intangible assets, others [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
[LineItems]
Nature of other intangible assets 0.00 0 0.00 0 0.00 0
[Abstract]
[Abstract]
intangible assets
Total additions to
0 6,85,111 0 6,85,111
intangible assets
Impairment loss
intangible assets
[Abstract]
0 0 0 93,113 0 93,113
assets, others
0 0 0 93,113 0 93,113
assets
assets [Abstract]
Other adjustments
0 0 0 0
0 0 0 0
intangible assets
-59,05,098 -55,93,331 0 5,91,998 59,05,098 61,85,329
assets
52

Classes of intangible assets [Axis] Other intangible assets, others [Member]
generated [Member]
[Member] [Member]
01/04/2020 01/04/2020 01/04/2020 01/04/2019 01/04/2019 01/04/2019
to to to to to to
31/03/2021 31/03/2021 31/03/2021 31/03/2020 31/03/2020 31/03/2020
[LineItems]
Nature of other intangible assets 0.00 0.00 0.00 0 0 0
[Abstract]
[Abstract]
intangible assets
Total additions to
0 0 6,85,111 6,85,111
intangible assets
Impairment loss
intangible assets
[Abstract]
0 0 0 0 93,113 93,113
assets, others
0 0 0 0 93,113 93,113
assets
assets [Abstract]
Other adjustments
0 0 0 0
0 0 0 0
intangible assets
-59,05,098 0 59,05,098 -55,93,331 5,91,998 61,85,329
assets
Disclosure of additional information intangible assets [Table] ..(1)

Company total intangible assets Other intangible assets Other intangible assets, others
Classes of intangible assets [Axis]
[Member] [Member] [Member]
Internally generated and other Internally generated and other Internally generated and other
Sub classes of intangible assets [Axis] than internally generated than internally generated than internally generated
intangible assets [Member] intangible assets [Member] intangible assets [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020 31/03/2021 31/03/2020
intangible assets [LineItems]
Useful lives or amortization rates
NA NA NA NA NA NA
intangible assets
Description of amortization method
- - - - - -
used
53
Disclosure of additional information intangible assets [Table] ..(2)

Other intangible assets, others
Classes of intangible assets [Axis]
[Member]
Intangible assets
Internally
other than
generated
Sub classes of intangible assets [Axis] internally
intangible assets
generated
[Member]
[Member]
01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of additional information intangible assets [Abstract]
Disclosure of additional information intangible assets [LineItems]
Useful lives or amortization rates intangible assets 3 yrs 3 yrs
Description of amortization method used straight line method straight line method

01/04/2020
to
31/03/2021
Disclosure of notes on intangible assets explanatory [TextBlock] [See below]
54
Disclosure of notes on intangible assets explanatory [Text Block]
Accumulated
depreciation
and
amortization
As at As at
As at As at As at
Charge for
Additions Deletions Deletions
31 March the year 31 March
1 April 2020 1 April 2020 31 March 2021
2021 2021
Plant and
equipment
Laboratory
equipment 69,05,19,718 8,35,67,785 - 77,40,87,503 47,10,64,290 11,30,58,635 - 58,41,22,925 18,99,64,578
Computer and
hardware 13,10,38,242 1,01,18,769 - 14,11,57,011 8,80,66,082 1,95,46,569 - 10,76,12,652 3,35,44,359
Office
equipments 1,35,51,304 13,16,922 - 1,48,68,226 74,21,172 27,81,774 - 1,02,02,948 46,65,278
Vehicles
5,50,000 - - 5,50,000 3,85,251 1,64,749 - 5,50,000 -
Furniture and
fixtures 13,37,831 72,000 - 14,09,831 11,29,154 97,204 - 12,26,358 1,83,473
Leasehold
improvements 13,71,23,308 49,13,284 - 14,20,36,592 8,97,25,737 2,02,62,797 - 10,99,88,534 3,20,48,058
Total plant
and
97,41,20,403 9,99,88,760 - 1,07,41,09,163 65,77,91,686 15,59,11,728 - 81,37,03,417 26,04,05,746
equipment
Intangible
assets
Software
3,59,08,352 - - 3,59,08,352 2,96,46,583 59,05,098 - 3,55,51,681 3,56,671
Total
intangible
3,59,08,352 - - 3,59,08,352 2,96,46,583 59,05,098 - 3,55,51,681 3,56,671
assets
Total
1,01,00,28,755 9,99,88,760 - 1,11,00,17,515 68,74,38,269 16,18,16,826 - 84,92,55,098 26,07,62,417
55
Accumulated
depreciation
and
amortization
As at As at
As at As at As at
Charge for
Additions Deletions Deletions
31 March the year 31 March
1 April 2019 1 April 2019 31 March 2020
2020 2020
Plant and
equipment
Laboratory
equipment 63,90,44,499 5,42,91,050 28,15,831 69,05,19,718 33,95,26,591 13,37,67,550 22,29,851 47,10,64,290 21,94,55,445
Computer and
hardware 12,53,42,948 94,07,551 37,12,257 13,10,38,242 7,08,83,433 2,01,52,778 29,70,129 8,80,66,082 4,29,72,160
Office
equipment 1,40,53,175 19,02,350 24,04,221 1,35,51,304 64,64,736 28,76,528 19,20,092 74,21,172 61,30,132
Vehicles
11,00,000 - 5,50,000 5,50,000 4,03,836 1,83,333 2,01,918 3,85,251 1,64,749
Furniture and
fixtures 16,94,569 50,500 4,07,238 13,37,831 12,89,423 2,46,969 4,07,238 11,29,154 2,08,677
Leasehold
improvements 13,31,79,710 1,74,94,800 1,35,51,202 13,71,23,308 7,51,44,380 2,68,41,216 1,22,59,859 8,97,25,737 4,73,97,552
Total plant
and
91,44,14,901 8,31,46,251 2,34,40,749 97,41,20,403 49,37,12,399 18,40,68,374 1,99,89,087 65,77,91,686 31,63,28,715
equipment
Intangible
assets
Software
3,53,16,354 6,85,111 93,113 3,59,08,352 2,34,61,254 62,78,442 93,113 2,96,46,583 62,61,769
Total
intangible
3,53,16,354 6,85,111 93,113 3,59,08,352 2,34,61,254 62,78,442 93,113 2,96,46,583 62,61,769
assets
Total
94,97,31,255 8,38,31,362 2,35,33,862 1,01,00,28,755 51,71,73,653 19,03,46,816 2,00,82,200 68,74,38,269 32,25,90,484
56
[200600] Notes - Subclassification and notes on liabilities and assets
Subclassification of trade receivables [Table] ..(1)

Classification of assets based on security
Classification of assets based on security [Axis] Unsecured considered good [Member]
[Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Subclassification and notes on liabilities and assets
[Abstract]
Trade receivables notes [Abstract]
Trade receivables [Abstract]
Subclassification of trade receivables
[Abstract]
Subclassification of trade receivables
[LineItems]
Breakup of trade receivables [Abstract]
Trade receivables, gross 30,52,33,907 24,62,73,194 (A) 30,52,33,907 (B) 24,62,73,194
Allowance for bad and doubtful debts 46,47,351 34,07,901 (C) 46,47,351 (D) 34,07,901
Total trade receivables 30,05,86,556 24,28,65,293 30,05,86,556 24,28,65,293
Details of trade receivables due by
directors, other officers or others
[Abstract]
Trade receivables due by directors 0 0
Trade receivables due by other officers 0 0
Details of trade receivables due by
firms or companies in which any director
is partner or director [Abstract]
Total trade receivables due by firms
or companies in which any director is 0 0
partner or director
Footnotes
(A) Receivables outstanding for a period exceeding six months from the date they became due for payment Considered Goods:
61247816 Considered doubtful: 4647354 Other receivable: Considered good: 239338737
(B) Receivables outstanding for a period exceeding six months from the date they became due for payment Considered Goods:
70531171 Considered doubtful: 3407901 Other receivable: Considered good: 172324122
(C) Provision for doubtful receivable
(D) Provision for doubtful receivable
Disclosure of breakup of provisions [Table] ..(1)

Classification based on time period [Axis] Long-term [Member] Short-term [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Provisions notes [Abstract]
Disclosure of breakup of provisions [Abstract]
Disclosure of breakup of provisions [LineItems]
Provisions [Abstract]
Provisions for employee benefits
[Abstract]
Provision gratuity 2,25,12,573 1,93,97,684 (A) 29,49,486 19,26,131
Provision other employee related
1,84,49,238 1,71,32,653
liabilities
Total provisions for employee benefits 2,25,12,573 1,93,97,684 (B) 2,13,98,724 (C) 1,90,58,784
CSR expenditure provision 0 0 0 0
Total provisions 2,25,12,573 1,93,97,684 2,13,98,724 1,90,58,784
57
Footnotes
(A) Provision for gratuity (refer note 3.34) Note 3.34: Employee benefits Defined contribution plans The Company makes
contributions, determined as a specified percentage of employees salaries, in respect of qualifying employees towards provident fund
and employees state insurance, which are defined contribution plans. The Company has no obligation other than to make the
specified contribution. The contributions are charged to the statement of profit and loss as they accrue. The amount recognized as an
expense towards contribution to provident fund and employee state insurance for the year aggregated to Rs. 9,614,675/- (previous
year: Rs. 11,107,572/-). Defined benefit plans The Company operates a post employment benefit plan that provides for gratuity
benefit to the employees of the Company. The gratuity plan entitles an employee, who has rendered at least five years of continuous
service, to receive one-half month’s salary for each year of completed service at the time of retirement/exit. 'The following table sets
set out the status of the gratuity plan as required under Accounting standard (AS) 15 “Employee Benefits” prescribed by Companies
(Accounting Standards) Rules, 2006, (‘the Rules’): Liability recognized in the balance sheet As at 31 March 2021 As at 31 March
2020 Present value of obligations 2,54,62,059 2,13,23,815 Fair value of plan assets - - Net liability recognized in the balance sheet
2,54,62,059 2,13,23,815 Classification into current/ non-current As at 31 March 2021 As at 31 March 2020 Current 29,50,660
19,26,131 Non-current 2,25,11,399 1,93,97,684 Change in present values of defined benefit obligation As at 31 March 2021 As at 31
March 2020 Opening defined benefit obligation 2,12,81,867 1,38,92,133 Current service cost 66,68,394 51,95,647 Interest cost
16,86,684 13,29,437 Actuarial loss/ (gain) (14,28,762) 16,93,933 Past service cost - - Benefits paid (27,46,125) (9,58,259) Expenses
recognized in statement of profit and loss For the year ended 31 March 2021 For the year ended 31 March 2020 Current service cost
66,26,446 51,95,647 Interest on defined benefit obligation 16,86,684 13,29,437 Net actuarial loss/ (gain) recognized in the current
year (14,28,762) 16,93,933 Past service cost - Total expense included in "employee benefits" 68,84,368 82,19,017 Principal actuarial
assumptions For the year ended 31 March 2021 For the year ended 31 March 2020 Discount rate as at the balance sheet
date6.25%6.25% Future salary increase8.00%8.00% Retirement age 58 years 58 years Experience adjustments For the year ended 31
March 2020For the year ended 31 March 2021 Defined benefit obligation 2,11,52,891 2,54,62,058 Plan assets - - Deficit 2,11,52,891
2,54,62,058 Experience adjustments on plan liabilities-5,20,186-14,28,762 Experience adjustments on plan assets - -
(B) Provision for compensated absences
(C) Provision for compensated absences
Loans and advances [Table] ..(1)

Classification of loans and advances [Axis] Loans and advances [Member] Security deposits [Member]
Classification of assets based on security [Axis] Unsecured considered good [Member] Unsecured considered good [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Loans and advances notes [Abstract]
Loans and advances [Abstract]
Disclosure of loans and advances [LineItems]
Loans and advances, gross 7,46,42,509 11,23,85,656 1,30,59,478 1,26,29,355
Allowance for bad and doubtful loans and
0 0 0 0
advances
Loans and advances 7,46,42,509 11,23,85,656 1,30,59,478 1,26,29,355
Details of loans and advances due by
[Abstract]
Loans and advances due by directors 0 0 0 0
Loans and advances due by other officers 0 0 0 0
Details of loans and advances due by firms
or companies in which any director is
partner or director [Abstract]
Loans and advances due by firms in
0 0 0 0
which any director is partner
Total loans and advances due
by firms or companies in which
0 0 0 0
any director is partner or
director
58

Classification of loans and advances [Axis] Other loans and advances [Member] Advance tax [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Loans and advances, gross 6,15,83,031 9,97,56,301 4,56,73,584 7,12,39,563
0 0 0 0
advances
[Abstract]
0 0 0 0
0 0 0 0
director

Other loans and advances, others
Classification of loans and advances [Axis] Advance income tax paid [Member]
[Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Loans and advances, gross (A) 4,56,73,584 (B) 7,12,39,563 (C) 1,59,09,447 (D) 2,85,16,738
0 0 0 0
advances
[Abstract]
0 0 0 0
0 0 0 0
director
Footnotes
(A) Advance tax, net of provision for tax Rs.21,818,364 (Previous year Rs 4,068,577)
(B) Advance tax, net of provision for tax Rs.21,818,364 (Previous year Rs 4,068,577)
(C) Balances with government authorities: 15507614, Prepaid expenses: 401833
(D) Balances with government authorities: 28414388, Prepaid expenses: 102350
59

Loans advances given suppliers
Classification of loans and advances [Axis] Loans and advances [Member]
[Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Loans and advances, gross 4,64,13,243 4,57,99,862 1,81,38,876 90,46,087
0 0 0 0
advances
Loans and advances 4,64,13,243 4,57,99,862 1,81,38,876 90,46,087
[Abstract]
0 0 0 0
0 0 0 0
director

Loans advances given employees
Classification of loans and advances [Axis] Other loans and advances [Member]
[Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Loans and advances, gross 10,22,646 9,71,535 2,72,51,721 3,57,82,240
0 0 0 0
advances
Loans and advances 10,22,646 9,71,535 2,72,51,721 3,57,82,240
[Abstract]
0 0 0 0
0 0 0 0
director
60

Classification of loans and advances [Axis] Prepaid expenses [Member]
Classification of assets based on security [Axis] Unsecured considered good [Member]
31/03/2021 31/03/2020
Subclassification and notes on liabilities and assets [Abstract]
Loans and advances, gross 2,72,51,721 3,57,82,240
Allowance for bad and doubtful loans and advances 0 0
Loans and advances 2,72,51,721 3,57,82,240
Details of loans and advances due by directors, other officers or others
[Abstract]
Loans and advances due by directors 0 0
Loans and advances due by other officers 0 0
Details of loans and advances due by firms or companies in which any
director is partner or director [Abstract]
Loans and advances due by firms in which any director is partner 0 0
Total loans and advances due by firms or companies in which any director
0 0
is partner or director
Classification of inventories [Table] ..(1)

Classification of inventories [Axis] Company total inventories [Member] Raw materials [Member]
01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020
[Abstract]
Inventories notes [Abstract]
Inventories [Abstract]
Classification of inventories [Abstract]
Details of inventories [LineItems]
Inventories 15,31,78,860 8,70,87,270 (A) 15,31,78,860 (B) 8,70,87,270
Cost or Net Cost or Net
Cost or Net Cost or Net
Realisable value, Realisable value,
Mode of valuation whichever is lower
Realisable value,
whichever is lower
Realisable value,
whichever is lower whichever is lower
Footnotes
(A) Lab consumables
(B) Lab consumables
61

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of subclassification and notes on liabilities and assets
explanatory [TextBlock]
Disclosure of notes on other long-term liabilities explanatory Textual information (9)
[TextBlock] [See below]
Trade payables, long-term 0 0
Others long-term, others 5,41,396

(A) 26,55,440
Total others, long-term 5,41,396 26,55,440
Total other long-term liabilities 5,41,396 26,55,440
Disclosure of notes on provisions explanatory [TextBlock] [See below]
Disclosure of notes on other current liabilities explanatory Textual information (11)
Current maturities of long-term debt (B) 4,65,80,292 (C) 13,29,13,460

Interest accrued but not due on borrowings 0 0
Interest accrued and due on borrowings 0 0
Interest accrued but not due on public deposits 0 0
Interest accrued and due on public deposits 0 0
Debentures claimed but not paid 0 0
Unpaid dividends 0 0
Application money received for allotment of securities and
0 0
due for refund, principal
Unpaid matured deposits and interest accrued thereon 0 0
Unpaid matured debentures and interest accrued thereon 0 0
Public deposit payable, current 0 0
Total other payables, current 0 0
Advance received from customers (D) 29,41,12,566 (E) 17,87,60,145

Other advance received (F) 6,33,82,123 (G) 8,44,87,134
Current liabilities portion of share application money pending
0 0
allotment
Other current liabilities, others (H) 6,56,18,283 (I) 6,17,63,543
Total other current liabilities 46,96,93,264 45,79,24,282
Disclosure of notes on loans and advances explanatory [TextBlock] [See below]
Other non-current assets, others (J) 2,08,04,392 (K) 7,33,51,423
Total other non-current assets 2,08,04,392 7,33,51,423
Bank Deposits (due to Bank Deposits (due to
mature after 12 months mature after 12 months
Nature of other non-current assets, others f rom repor t i n g d a t e ) a f rom repor t i n g d a t e ) a
n d Interst accrued on n d Interst accrued on
fixed deposits fixed deposits
Disclosure of notes on inventories explanatory [TextBlock] [See below]
Disclosure of notes on trade receivables explanatory [TextBlock] [See below]
Aggregate amount of trade receivables outstanding for period
0 0
exceeding six months
Disclosure of notes on cash and bank balances explanatory [TextBlock] [See below]
Fixed deposits with banks 0 0
Other balances with banks (L) 6,55,08,673 (M) 6,01,27,355

Total balance with banks 6,55,08,673 6,01,27,355
Cash on hand 1,59,336 2,20,648
Total cash and cash equivalents 6,56,68,009 6,03,48,003
Other bank balances (N) 10,78,75,301 (O) 3,05,19,681

Total cash and bank balances 17,35,43,310 9,08,67,684
Total balances held with banks to extent held as
margin money or security against borrowings, 0 0
guarantees or other commitments
Bank deposits with more than twelve months maturity 0 0
Disclosure of notes on other current assets explanatory [TextBlock] [See below]
Other current assets, others (P) 1,43,99,287 (Q) 56,58,820
Total other current assets 1,43,99,287 56,58,820
62
Footnotes
(A) Deferred rent
(B) *pertains to current maturities of long-term borrowing. For details refer note 3.04 i.e related to Note of long term borrowings
(C) *pertains to current maturities of long-term borrowing. For details refer note 3.04 i.e related to Note of long term borrowings
(D) ** includes payable to related parties. Refer note 3.28 i.e from MedGenome Inc.
(E) ** includes payable to related parties. Refer note 3.28 i.e from MedGenome Inc.
(F) Unearned revenue
(G) Unearned revenue
(H) Payable to employees- 21799478 Provision for expenses- 29154239 Statutory liabilities- 9087958 Capital creditors-5576608
(I) Loan from director**- 2100000 ** includes payable to related parties. Refer note 3.27 Payable to employees- 30657189 Provision
for expenses-22262276 Statutory liabilities- 7204878 Capital creditors- 1639200
(J) Bank deposits (due to mature after 12 months from reporting date)*-2225400 Interest accrued on fixed deposits-829205 MAT
Credit Entitlement: 17749787 *Bank deposit includes deposit of Rs.2,225,400 (previous year Rs. 5,146,637) against bank guarantee
issued in favour of statutory authorities. Also in previous year Rs. 62,863,178 places as security with HDFC bank Limited.
(K) Bank deposits (due to mature after 12 months from reporting date)*- 68300578 Interest accrued on fixed deposits-5050845
*Bank deposit includes deposit of Rs.2,225,400 (previous year Rs. 5,146,637) against bank guarantee issued in favour of statutory
authorities. Also in previous year Rs. 62,863,178 places as security with HDFC bank Limited.
(L) 'Balances with banks -In current accounts : 46301513 - In EEFC accounts: 19207160 - In deposit accounts* : Nil *Bank deposits
of Rs. 14,438,869 (previous year Rs. 55,127,135) are deposits placed with bankers against which bank guarantees have been issued
to statutory authorities and Rs. 93,436,432 (previous year Rs. 31,653,862) placed as security with HDFC Bank Limited.
(M) 'Balances with banks -In current accounts : 2450313 - In EEFC accounts: 1368012 - In deposit accounts* : 56309030 *Bank
deposits of Rs. 14,438,869 (previous year Rs. 55,127,135) are deposits placed with bankers against which bank guarantees have been
issued to statutory authorities and Rs. 93,436,432 (previous year Rs. 31,653,862) placed as security with HDFC Bank Limited.
(N) 'Deposit accounts (due to mature within 12 months from reporting date)* *Bank deposits of Rs. 14,438,869 (previous year Rs.
55,127,135) are deposits placed with bankers against which bank guarantees have been issued to statutory authorities and Rs.
93,436,432 (previous year Rs. 31,653,862) placed as security with HDFC Bank Limited. Details of bank balances / deposits As at 31
March 2021 As at 31 March 2020 Bank balances available on demand/deposits with original maturity of 3 months or less included
under ‘Cash and cash equivalents’ - 5,63,09,030 Bank deposits due to mature within 12 months of the reporting date included under
'other bank balances' 10,78,75,301 3,05,19,681 Bank deposits due to mature after 12 months of the reporting date included under
'other non-current assets' (refer note 3.13) 22,25,400 6,83,00,578
(O) 'Deposit accounts (due to mature within 12 months from reporting date)* *Bank deposits of Rs. 14,438,869 (previous year Rs.
55,127,135) are deposits placed with bankers against which bank guarantees have been issued to statutory authorities and Rs.
93,436,432 (previous year Rs. 31,653,862) placed as security with HDFC Bank Limited. Details of bank balances / deposits As at 31
March 2021 As at 31 March 2020 Bank balances available on demand/deposits with original maturity of 3 months or less included
under ‘Cash and cash equivalents’ - 5,63,09,030 Bank deposits due to mature within 12 months of the reporting date included under
'other bank balances' 10,78,75,301 3,05,19,681 Bank deposits due to mature after 12 months of the reporting date included under
'other non-current assets' (refer note 3.13) 22,25,400 6,83,00,578
(P) Interest accrued on fixed deposits
(Q) Interest accrued on fixed deposits
63
Disclosure of notes on other long-term liabilities explanatory [Text Block]
Other long-term liabilities
As at As at
31 March 2021 31 March 2020
Deferred rent 5,41,396 26,55,440
5,41,396 26,55,440
64
Disclosure of notes on provisions explanatory [Text Block]
Long-term provisions
As at As at
31 March 2021 31 March 2020
Provision for employee benefits
Gratuity (refer note 3.34) 2,25,12,573 1,93,97,684
2,25,12,573 1,93,97,684
Employee benefits
Defined contribution plans
The Company makes contributions, determined as a specified percentage of employees

salaries, in respect of qualifying employees towards provident fund and employees state
insurance, which are defined contribution plans. The Company has no obligation other than to
make the specified contribution. The contributions are charged to the statement of profit and
loss as they accrue. The amount recognized as an expense towards contribution to provident
fund and employee state insurance for the year aggregated to Rs. 9,614,675/- (previous year:
Rs. 11,107,572/-).
Defined benefit plans
The Company operates a post employment benefit plan that provides for gratuity benefit to the
employees of the Company. The gratuity plan entitles an employee, who has rendered at least
five years of continuous service, to receive one-half months salary for each year of completed
service at the time of retirement/exit.
The following table sets set out the status of the gratuity plan as required under Accounting
standard (AS) 15 Employee Benefits prescribed by Companies (Accounting Standards) Rules,
2006, (the Rules):
Liability recognized in the balance sheet
As at As at
31 March 2021 31 March 2020
Present value of obligations

2,54,62,059 2,13,23,815
Fair value of plan assets

- -
65
Net liability recognized in the balance sheet

2,54,62,059 2,13,23,815
Classification into current/ non-current
As at As at
31 March 2021 31 March 2020
Current
29,50,660 19,26,131
Non-current
2,25,11,399 1,93,97,684
Change in present values of defined benefit obligation
As at As at
31 March 2021 31 March 2020
Opening defined benefit obligation

2,12,81,867 1,38,92,133
Current service cost

66,68,394 51,95,647
Interest cost
16,86,684 13,29,437
Actuarial loss/ (gain)

(14,28,762) 16,93,933
Past service cost

- -
Benefits paid
(27,46,125) (9,58,259)
Expenses recognized in statement of profit and loss
For the year

For the year ended
ended
31 March 2020
31 March 2021
Current service cost

66,26,446 51,95,647
Interest on defined benefit obligation

16,86,684 13,29,437
Net actuarial loss/ (gain) recognized in the current year

(14,28,762) 16,93,933
66
Past service cost

-
Total expense included in "employee benefits"

68,84,368 82,19,017
Principal actuarial assumptions
For the year

For the year ended
ended
31 March 2020
31 March 2021
Discount rate as at the balance sheet date 6.25% 6.25%
Future salary increase 8.00% 8.00%
Retirement age 58 years 58 years
Experience adjustments
For the year

For the year ended
ended
31 March 2021
31 March 2020
Defined benefit obligation

2,11,52,891 2,54,62,058
Plan assets
- -
Deficit
2,11,52,891 2,54,62,058
Experience adjustments on plan liabilities -5,20,186 -14,28,762
Experience adjustments on plan assets

- -
Short-term provisions
As at As at
31 March 2021 31 March 2020
67
Provision for employee benefits
Provision for gratuity (refer note 3.34) 29,49,486 19,26,131
Provision for compensated absences 1,84,49,238 1,71,32,653
2,13,98,724 1,90,58,784
68
Disclosure of notes on other current liabilities explanatory [Text Block]
Other current liabilities
As at As at
31 March 2021 31 March 2020
Current maturities of long-term debt* 4,65,80,292 13,29,13,460
Advance from customer ** 29,41,12,566 17,87,60,145
Unearned revenue 6,33,82,123 8,44,87,134
Payable to employees 2,17,99,478 3,06,57,189
Provision for expenses 2,91,54,239 2,22,62,276
Statutory liabilities 90,87,958 72,04,878
Capital creditors 55,76,608 16,39,200
46,96,93,264 45,79,24,282
*pertains to current maturities of long-term borrowing.
** includes advance from related parties.
69
Disclosure of notes on loans and advances explanatory [Text Block]
Long-term loans and advances
As at As at
31 March 2021 31 March 2020
Unsecured and considered good
Security deposits 1,30,59,478 1,26,29,355
Advance tax, net of provision for tax Rs.21,818,364 (Previous year Rs 4,068,577) 4,56,73,584 7,12,39,563
Balances with government authorities 1,55,07,614 2,84,14,388
Prepaid expenses 4,01,833 1,02,350
7,46,42,509 11,23,85,656
Short-term loans and advances
As at As at
31 March 2021 31 March 2020
Prepaid expenses 2,72,51,721 3,57,82,240
Advances to employees 10,22,644 9,71,535
Advances to suppliers 1,81,38,876 90,46,087
4,64,13,241 4,57,99,862
70
Disclosure of notes on inventories explanatory [Text Block]
Inventories
As at As at
31 March 2021 31 March 2020
Lab consumables 15,31,78,860 8,70,87,270
15,31,78,860 8,70,87,270
71
Disclosure of notes on trade receivables explanatory [Text Block]
Trade receivables
As at As at
31 March 2021 31 March 2020
Unsecured
Receivables outstanding for a period exceeding six months from the date they became due for
payment
Considered good
6,12,47,816 7,05,31,171
Considered doubtful
46,47,351 34,07,901
6,58,95,167 7,39,39,072
Less: Provision for doubtful receivable

46,47,351 34,07,901
(A)
6,12,47,816 7,05,31,171
Other receivable
Considered good
23,93,38,737 17,23,34,122
Considered doubtful - -
23,93,38,737 17,23,34,122
Less: Provision for doubtful receivable - -
(B)
23,93,38,737 17,23,34,122
(A)+(B) 30,05,86,553 24,28,65,293
72
73
Disclosure of notes on cash and bank balances explanatory [Text Block]
Cash and bank balances
As at
As at
31 March
31 March 2021
2020
Cash and cash equivalents
Cash on hand
1,59,336 2,20,648
Balances with banks
-In current accounts

4,63,01,513 24,50,313
- In EEFC accounts
1,92,07,160 13,68,012
- In deposit accounts*
- 5,63,09,030
6,56,68,009 6,03,48,003
Other bank balances
Deposit accounts (due to mature within 12 months from reporting date)*

10,78,75,301 3,05,19,681
17,35,43,310 9,08,67,684
*Bank deposits of Rs. 14,438,869 (previous year Rs. 55,127,135) are deposits placed with bankers against
which bank guarantees have been issued to statutory authorities and Rs. 93,436,432 (previous year Rs.
31,653,862) placed as security with HDFC Bank Limited.
Details of bank balances / deposits
As at
As at
31 March
31 March 2021
2020
Bank balances available on demand/deposits with original maturity of 3 months or less included under Cash
74
and cash equivalents - 5,63,09,030
Bank deposits due to mature within 12 months of the reporting date included under 'other bank balances'
10,78,75,301 3,05,19,681
Bank deposits due to mature after 12 months of the reporting date included under 'other non-current assets'
(refer note 3.13) 22,25,400 6,83,00,578
Disclosure of notes on other current assets explanatory [Text Block]
Other current assets
As at As at
31 March 2021 31 March 2020
Interest accrued on fixed deposits 1,43,99,287 56,58,820
1,43,99,287 56,58,820
75
[200700] Notes - Additional disclosures on balance sheet

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of additional balance sheet notes explanatory [TextBlock] [See below]
Guarantees (A) 1,66,64,269 (B) 6,03,21,485
Other money for which company is contingently liable (C) 20,83,89,625 (D) 23,98,28,801
Total contingent liabilities 22,50,53,894 30,01,50,286
Total contingent liabilities and commitments 22,50,53,894 30,01,50,286
Amount of dividends proposed to be distributed to equity shareholders 0 0
Amount of per share dividend proposed to be distributed to equity
[INR/shares] 0 [INR/shares] 0
shareholders
Deposits accepted or renewed during period 0 0
Deposits matured and claimed but not paid during period 0 0
Deposits matured and claimed but not paid 0 0
Deposits matured but not claimed 0 0
Interest on deposits accrued and due but not paid 0 0
Share application money received during year 0 0
Share application money paid during year 0 0
Amount of share application money received back during year 0 0
Amount of share application money repaid returned back during year 0 0
Number of person share application money paid during year [pure] 0 [pure] 0
Number of person share application money received during year [pure] 0 [pure] 0
Number of person share application money paid as at end of year [pure] 0 [pure] 0
Number of person share application money received as at end of year [pure] 0 [pure] 0
Whether audit of cost records of company has been mandated
No
under Rules specified in SN 1
Unclaimed share application refund money 0 0
Unclaimed matured debentures 0 0
Unclaimed matured deposits 0 0
Interest unclaimed amount 0 0
Number of warrants converted into equity shares during period [pure] 0 [pure] 0
Number of warrants converted into preference shares during period [pure] 0 [pure] 0
Number of warrants converted into debentures during period [pure] 0 [pure] 0
Number of warrants issued during period (in foreign currency) [pure] 0 [pure] 0
Number of warrants issued during period (INR) [pure] 0 [pure] 0
Footnotes
(A) Performance and financial guarantees given by banks on behalf of the Company
(B) Performance and financial guarantees given by banks on behalf of the Company
(C) Disputed demand for income tax and service tax
(D) Disputed demand for income tax and service tax
76
Disclosure of additional balance sheet notes explanatory [Text Block]
* The Group has payables amounting to Rs. 42,583,447 in foreign currency which is outstanding for a
period in excess of that specified under notification no. FED Master Direction No. 17/2016-17 on
Import of Goods and Services and as amended from time to time.
For the
For the year ended
year ended
Particulars
31 March
31 March 2020
2021
Trade payables outstanding for a period in excess of that specified under notification above.
4,25,83,447 -
Subsequent to the balance sheet date, the Group has paid entire amount out of above payables.
Management does not expect the outcome of this matter to have a material impact on the financial
statements.
*Special Bank Notes

-
The disclosures regarding details of SBNs held and transacted during 8 November 2016 to 30 December 2016
has not been made in these financial statements since the requirement does not pertain to financial year ended 31
March 2021 and 31 March 2020.
*Transfer pricing
The Finance Act, 2001 has introduced, with effect from assessment year 2002-03 (effective 1 April 2001),
detailed transfer pricing regulations for computing the taxable income and expenditure from 'international
transactions' between 'associated enterprises' on 'arm's length' basis. These regulations, inter alia, also require the
maintenance of prescribed documents and information including furnishing a report from an Accountant within
the due date of filing return of income. The Group has undertaken necessary steps to comply with the Transfer
Pricing regulations and the prescribed certificate from the accountant will be obtained for the year ended 31
March 2021 within the due date. The management is of the opinion that the international transactions are at
arm's length , and hence the aforesaid legislation will not have any impact on the financial statements,
particularly on the amount of tax expense and that of the provision for taxation.
*Covid Note:
In March 2020, the World Health Organization declared COVID-19 to be a pandemic. The Company has
adopted measures to curb the spread of infection in order to protect the health of its employees and ensure
business continuity with minimal disruption.
There has been no significant impact of COVID-19 on the Company based on internal and external information
while finalising various estimates in relation to its financial statement captions upto the date of approval of the
financial statements by the Board of Directors. The Company will continue to closely monitor any material
changes to future economic conditions.
* Additional Information, as required under schedule III to
77
the Companies Act, 2013, of enterprises consolidated as

subsidiary is as under
Net Assets i.e. total

Share in profit
Name of the Enterprise assets minus total
or loss
liabilities
As % of
As % of consolidated
Amount consolidated Amount
net assets
loss
Parent
MedGenome Labs Limited 88% -14,78,01,830 108% 11,37,80,684
Subsidiary
Immucare Diagnostics Private Limited 12% -2,03,54,141 -5% -57,34,098
Adjustments arising out of consolidation 0.39% -6,50,000

- -
Total 100% -16,88,05,971 100% 10,49,58,995
*Previous year figures have been regrouped and reclassified, where necessary to conform to the current year's presentation.
[200800] Notes - Disclosure of accounting policies, changes in accounting policies and estimates
01/04/2020
to
31/03/2021
Disclosure of accounting policies, change in accounting policies and Textual information (18)
changes in estimates explanatory [TextBlock] [See below]
78
Disclosure of accounting policies, change in accounting policies and changes in estimates explanatory [Text Block]
1. Background
MedGenome Labs Limited (" the Company ") was incorporated on 8 April 2013 as a private limited company. Pursuant to order received
from Registrar of Companies with fresh certificate of incorporation, the Company got converted to public company w.e.f. 18 January 2018.
The Company is a subsidiary of MedGenome Inc., ("the Holding Company"). The Company offers molecular diagnostic testing services for
genetic diseases and drug metabolism.
Disclosure relating to entities considered in the Consolidated Financial Statements
Country of Current Year Percentage Holding Previous Year Percentage Holding

Name of the Company Relation
incorporation – Share – Share
Holding
Medgenome Labs Limited India Not Applicable Not Applicable
Company
Immucare Diagnostic Private Subsidiary

India 65% 65%
Limited Company
2. Significant accounting policies
The accounting policies set out below have been applied consistently to the periods presented in these consolidated financial statements.
a. Basis of preparation of consolidated financial statements
The consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in India (GAAP) under the
historical cost convention on the accrual basis. GAAP comprises accounting standards as prescribed under Section 133 of the Companies
Act, 2013 (‘Act’) read with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Companies Act, 2013 ("the
2013 Act"), and Accounting Standards (‘AS’)/guidance notes issued by Institute of Chartered Accountants of India (ICAI) and other
generally accepted accounting principles in India. The consolidated financial statements are presented in Indian rupees.
Principles of Consolidation:
The consolidated financial statements of the Company and its subsidiaries ("the Group") are prepared in accordance with generally accepted
accounting principles applicable in India, and the Accounting Standard AS 21 "Consolidated financial statements", notified under Section I
33 of the Companies Act, 2013, read together with Rule 7 of the Companies (Accounts) Rules 2014.
The financial statements of MedGenome and its subsidiary have been combined on a line-by-line basis by adding together the book value of
all the items of assets, liabilities, incomes and expenses after eliminating all inter-company balances / transactions and the resultant
unrealized gain/loss. The Company has subsidiary named Immucare Diagnostics Private Limited based out of Kerala. It has 65%
shareholding in this Company.
b. Use of estimates
79
The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (GAAP) requires
management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets,
liabilities, income and expenses and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ
from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is
recognized prospectively in current and future periods.
Estimation uncertainty due to impact of COVID-19: The World Health Organization (WHO) on March 11, 2020, has declared the novel
coronavirus (COVID-19) outbreak a global pandemic. The Group believes that this is not just a public health crisis; it is a crisis that will
affect every sector including economy. The outbreak has resulted into disturbance and slowdown of economic activity throughout the world
and is affecting operations of the Company , by way of interruption in diagnostic services, movement of samples collected for providing
diagnostic services, unavailability of personnel, temporary closure of laboratories etc.
The Holding Company has undertaken to provide financial and other support to the Company as may be required to enable it continue in
operational existence and therefore, to enable to realize its assets and discharge its liabilities in the normal course of business for a period of
at least 12 months from the date of the balance sheet.
The Company has considered the possible effects, if any, that may impact the carrying amounts of inventories, receivables, intangibles and
basis such analysis no material impact has been ascertained. In making the assumptions and estimates relating to the uncertainties in relation
to the recoverable amounts, Company has considered subsequent events, internal and external information and evaluated economic
conditions prevailing from time to time both before and after the outbreak. The impact of COVID-19 on the Company’s consolidated
financial statements may differ from that estimated as at the date of approval of these consolidated financial statements.
c. Plant and equipment and intangible assets
Plant and equipment are carried at cost of acquisition or construction less accumulated depreciation and/or accumulated impairment loss, if
any. The cost of an item of plant and equipment comprises its purchase price, including import duties and other non-refundable taxes or
levies and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discounts and rebates that
are deducted in arriving at the purchase price.
Subsequent expenditures related to an item of plant and equipment are added to its book value only if they increase the future benefits from
the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day
repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which
such expenses are incurred.
Plant and equipment acquired wholly or partly with specific grant/subsidy from government, are recorded at the net acquisition cost to the
group.
Borrowing costs are interest and other costs (including exchange differences arising from foreign currency borrowings to the extent that they
are regarded as an adjustment to interest costs) incurred by the Group in connection with the borrowing of funds. Borrowing costs directly
attributable to acquisition or construction of those tangible fixed assets which necessarily take a substantial period of time to get ready for
their intended use are capitalised. Other borrowing costs are recognized as an expense in the period in which they are incurred.
Cost of plant and equipment not ready for use before the reporting date is disclosed as capital work-in-progress. Advances paid towards the
acquisition of fixed assets outstanding as of each reporting date is disclosed under long term loans and advances.
80
Leases under which the Group assumes substantially all the risks and rewards of ownership are classified as finance leases. Assets taken on
finance lease are initially capitalised at fair value of the asset or present value of the minimum lease payments at the inception of the lease,
whichever is lower. Lease payments are apportioned between the finance charge and the reduction of the outstanding liability. The finance
charge is allocated to periods during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the
liability for each period.
Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying
amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.
Plant and equipment and intangible assets (continued)
The Group has provided for depreciation using straight line method over the useful life of the assets as prescribed under Part C of Schedule II
of the Companies Act, 2013, except in the case of the following asset, which are depreciated based on useful lives estimated by the
management:
Asset category Useful life
Lab equipment 5 years
Furniture and fixture 3 years
Computer & Hardware 3-6 Years
Office Equipment's 3-5 Years
Leasehold Improvements 5 Years
Software & Licenses 3 Years
Vehicles 3 Years
For these classes of assets, based on internal technical assessment the management believes that the useful lives as given above best represent
the period over which management expects to use these assets. Hence, the useful lives for these assets are different from the useful lives as
prescribed under Part C of Schedule II to the Companies Act, 2013.
Leasehold improvements are amortized over the primary period of lease or the estimated useful life of such assets, whichever is shorter.
81
Amortization method and useful lives are reviewed at each reporting date. If the useful life of an asset is estimated to be significantly
different from previous estimates, the amortization period is changed accordingly. If there has been a significant change in the expected
pattern of economic benefits from the asset, the amortization method is changed to reflect the changed pattern.
Intangible fixed assets:
Acquired intangible assets
Intangible assets that are acquired by the Group are measured initially at cost. After initial recognition, an intangible asset is carried at its cost
less any accumulated amortization and any accumulated impairment loss.
Subsequent expenditure is capitalised only when it increases the future economic benefits from the specific asset to which it relates.
Intangible assets are amortized over the period the Group expects to derive economic benefit from their use. The management believes that
the period of amortization is representative of the period over which the Group expects to derive economic benefits from the use of the
assets.
Internally generated intangible assets
Internally generated goodwill is not recognized as an asset. With regard to other internally generated intangible assets:
1. Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding,
is recognized in the statement of profit and loss as incurred.
2. Development activities involve a plan or design for the production of new or substantially improved products or processes.
Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and
commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete
development and to use the asset. The expenditure capitalised includes the cost of materials, direct labor, overhead costs that are directly
attributable to preparing the asset for its intended use, and directly attributable borrowing costs (in the same manner as in the case of
tangible fixed assets). Other development expenditure is recognized in the statement of profit and loss as incurred.
Subsequent expenditure is capitalised only when it increases the future economic benefits from the specific asset to which it relates.
Intangible assets are amortized over the period the Group expects to derive economic benefit from their use, i.e. 5 years. The
management believes that the period of amortization is representative of the period over which the Group expects to derive economic
82
benefits from the use of the assets.
d. Impairment of plant and equipment
The Group assesses at each balance sheet date whether there is any indication that an asset or a group of assets comprising a cash generating
unit may be impaired. If any such indication exists, the Group estimates the recoverable amount of the asset. For an asset or group of assets
that does not generate largely independent cash in-flows, the recoverable amount is determined for the cash-generating unit to which the asset
belongs. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than
its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is
recognized in the statement of profit and loss. If at the balance sheet date there is an indication that a previously assessed impairment loss no
longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciable
historical cost. An impairment loss is reversed only to the extent that the carrying amount of asset does not exceed the net book value that
would have been determined; if no impairment loss had been recognized.
e. Operating leases
Assets acquired under leases other than finance leases are classified as operating leases. The total lease rentals (including scheduled rental
increases) in respect of an asset taken on operating lease are charged to the statement of profit and loss on a straight line basis over the lease
term unless another systematic basis is more representative of the time pattern of the benefit.
f. Investments
Investments that are readily realizable and intended to be held for not more than a year from the date of acquisition are classified as current
investments. All other investments are classified as long-term investments. However, that part of long term investments which is expected
to be realized within 12 months after the reporting date is also presented under ‘current assets’ as “current portion of long term
investments”.
Long-term investments (including current portion thereof) are carried at cost less any other-than-temporary diminution in value,
determined separately for each individual investment. Current investments are carried at lower of cost and fair value determined on an
individual investment basis.
On disposal of the investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement
of profit and loss.
Any reductions in the carrying amount and any reversals of such reductions are charged or credited to the statement of profit and loss.
g. Employee benefits
Short-term employee benefits:
Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee
benefits. These benefits include salaries and wages, bonus and ex-gratia. The undiscounted amount of short-term employee benefits
to be paid in exchange for employee services is recognized as an expense over the period of the service rendered by the employees.
Post-employment benefits:
Defined contribution plans
83
A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate
entity and has no obligation to pay any further amounts. The Group makes specified monthly contributions towards employee
provident fund to Government administered provident fund scheme which is a defined contribution plan. The Group contribution is
recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service.
Defined benefit plans
The Group gratuity benefit scheme is a defined benefit plan. The Group net obligation in respect of a defined benefit plan is
calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior
periods; that benefit is discounted to determine its present value. Any unrecognized past service costs and the fair value of any plan
assets are deducted. The calculation of the Group obligation is performed annually by a qualified actuary using the projected unit
credit method.
The Group recognizes all actuarial gains and losses arising from defined benefit plans immediately in the statement of profit and
loss. All expenses related to defined benefit plans are recognized in employee benefits expense in the statement of profit and loss.
Compensated absences
Compensated absences liability is accrued based on an actuarial valuation at the balance sheet date, carried out by an independent
actuary using the projected unit credit method.
To the extent the group does not have an unconditional right to defer the utilization or encashment of the accumulated compensated
absences, the liability determined based on actuarial valuation is considered to be a current liability.
Actuarial gains and losses are recognized immediately in the statement of profit and loss.
h. Revenue recognition
Revenue is primarily derived from rendering of molecular diagnostic testing services.
Revenue is recognized when there is conclusive evidence of a contractual arrangement with customers, services have been rendered, the fee
is fixed or determinable and collectability is reasonably assured. Conclusive evidence of an arrangement is established when the group
enters into an agreement with its customers with terms and conditions which describe the services and the related payments are legally
enforceable. The Group considers revenue to be determinable when the services have been provided in accordance with the agreement.
Revenue from services provided to academic and research partners is based on the price per test mentioned in the agreements entered into
with them. Revenue is recognized upon completion of test results and issue of reports, provided the consideration is reliably determinable
and no significant uncertainty exists regarding the collection of the consideration.
Revenue from retail samples represents sequencing services provided to patient referred by hospitals, reports of which is used by the doctors
to plan treatment of patient. Revenue for retail samples are recognized as and when services are rendered to various customers.
Unbilled revenues' included in other current assets represent cost and earnings in excess of billings as at the balance sheet date. 'Unearned
revenues' included in current liabilities represent billing in excess of revenue recognized.
Interest income is recognized using the time-proportion method, based on the rates implicit in the transaction.
i. Foreign currency transactions
84
Transactions:
The Group is exposed to foreign currency transactions including foreign currency revenues, purchase of goods and borrowings.
Foreign exchange transactions during the year are recorded at the rates of exchange prevailing on the dates of the respective
transactions.
Exchange differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit
and loss of the year.
Translation:
Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are translated at the exchange rates
on that date, the resultant exchange differences are recognized in the statement of profit and loss.
Non-monetary items which are carried in terms of historical cost denominated in foreign currency are reported using the
exchange rate on the date of the transaction.
j. Provisions
A provision is recognized if, as a result of a past event, the Group has a present obligation that can be estimated reliably, and it is
probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognized at the best
estimate of the expenditure required to settle the present obligation at the balance sheet date. The provisions are measured on an
undiscounted basis.
Onerous contracts
A contract is considered as onerous when the expected economic benefits to be derived by the Group from the contract are lower
than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the
lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision
is established, the Group recognizes any impairment loss on the assets associated with that contract.
Contingencies
Provision in respect of loss contingencies relating to claims, litigation, assessment, fines, penalties, etc. are recognized when it is
probable that a liability has been incurred and the amount can be estimated reliably.
k. Contingent liabilities
A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not,
require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant
provisions, but are disclosed unless the possibility of outflow of resources is remote.
l. Taxation
85
Income-tax expense comprises current tax (i.e. amount of tax for the period determined in accordance with the income-tax law) and deferred
tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period).
Income-tax expense is recognized in the statement of profit and loss except that tax expense related to items recognized directly in reserves
is also recognized in those reserves.
Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the applicable tax rates and tax
laws. Deferred tax is recognized in respect of timing differences between taxable income and accounting income i.e. differences that
originate in one period and are capable of reversal in one or more subsequent periods. The deferred tax charge or credit and the
corresponding deferred tax liabilities or assets are recognized using the tax rates and tax laws that have been enacted or substantively
enacted by the balance sheet date. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be
realized in future; however, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are
recognized only if there is a virtual certainty supported by convincing evidence that sufficient future taxable income will be available
against which such deferred tax assets can be realized. Deferred tax assets are reviewed as at each balance sheet date and written down or
written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realized.
Assets and liabilities representing current and deferred tax are disclosed on a net basis when there is a legally enforceable right to set off and
management intends to settle the asset and liability on a net basis.
Minimum Alternative Tax (‘MAT’) under the provisions of the Income-tax Act, 1961 is recognized as current tax in the statement of profit
and loss. The credit available under the Act in respect of MAT paid is recognized as an asset only when and to the extent there is convincing
evidence that the Group will pay normal income tax during the period for which the MAT credit can be carried forward for set-off against
the normal tax liability. MAT credit recognized as an asset is reviewed at each balance sheet date and written down to the extent the
aforesaid convincing evidence no longer exists.
The Group offsets, on a year on year basis, the current tax assets and liabilities, where it has a legally enforceable right and where it intends
to settle such assets and liabilities on a net basis.
m. Earnings per share (‘EPS’)
The basic earnings per share is computed by dividing the net profit after tax for the period by the weighted average number of equity shares
outstanding during the period. Diluted earnings per share, if any is computed using the weighted average number of equity shares and
dilutive potential equity share outstanding during the period except when the results would be anti-dilutive. Diluted potential equity shares
are deemed converted as of the beginning of the period, unless issued at a later date.
n. Cash and cash equivalents
Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an
original maturity of three months or less from the balance sheet date, but excludes restricted cash balances.
o. Cash flow statement
Cash flows are reported using the indirect method, whereby net profits/loss before tax is adjusted for the effects of transactions of a non-cash
nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing
and financing activities of the group are segregated.
86
p. Inventory
Inventories which comprise only consumables for medical process are valued at cost or net realizable value whichever is less. Cost of
inventories comprises purchase price, and other costs incurred in bringing the inventories to their present location and condition. The Group
uses FIFO method for accounting of inventory.
Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated
costs necessary to make the sale.
The comparison of cost and net realizable value is made on an item-by-item basis. The provision for inventory obsolescence is assessed on
an annual basis and is provided as considered necessary.
q. Current and non current classification
All assets and liabilities are classified into current and non-current.
(I) Assets
An asset is classified as current when it satisfies any of the following criteria:

a. It is expected to be realized in, or is intended for sale or consumption in, the Company’s normal operating cycle;
b. It is held primarily for the purpose of being traded;
c. It is expected to be realized within 12 months after the reporting date; or
d. It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the
reporting date.
All other assets are classified as non-current.
(ii) Liabilities
A liability is classified as current when it satisfies any of the following criteria:

a. It is expected to be settled in the Company’s normal operating cycle;
b. It is held primarily for the purpose of being traded;
c. It is due to be settled within 12 months after the reporting date;
d. The Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.
All other liabilities are classified as non-current.
(iii) Operating cycle
Operating cycle is the time between the acquisition of assets for processing and their realization in cash or cash equivalents. The
Company has ascertained its operating cycle being a period of 12 months for the purpose of classification of assets and liabilities into
current and non-current.
87
[201700] Notes - Government grants

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of notes on government grants explanatory [TextBlock]
Capital subsidies or grants received from government authorities 0 0
Revenue subsidies or grants received from government authorities 0 0
[201200] Notes - Employee benefits
Disclosure of defined benefit plans [Table] ..(1)

Defined benefit plans [Axis] Domestic defined benefit plans [Member]
Defined benefit plans categories [Axis] Gratuity
01/04/2020 01/04/2019
to to 31/03/2019
31/03/2021 31/03/2020
Disclosure of defined benefit plans [Abstract]
Disclosure of defined benefit plans [LineItems]
Textual information (19) Textual information (20)
Description of accounting policy for defined benefit plans [See below] [See below]
Reconciliation of changes in present value of defined benefit
obligation [Abstract]
Changes in defined benefit obligation, at present value
[Abstract]
Increase (decrease) through current service cost, defined
66,68,394 51,95,647
benefit obligation, at present value
Increase (decrease) through interest cost, defined benefit
16,86,684 13,29,437
obligation, at present value
Increase (decrease) through actuarial losses (gains),
-14,28,762 16,93,933
defined benefit obligation, at present value
Decrease through benefits paid, defined benefit obligation,
-27,46,125 -9,58,259
at present value
Total changes in defined benefit obligation, at present value 1,25,29,965 57,89,410
Defined benefit obligation, at present value at end of period 2,54,62,059 2,13,23,815 2,13,23,815
Reconciliation of changes in fair value of plan assets [Abstract]
Recognised assets and liabilities of defined benefit plans
[Abstract]
Recognised liabilities, defined benefit plan 2,54,62,059 2,13,23,815
Recognised assets, defined benefit plan 0 0
Net liability (asset) of defined benefit plans 2,54,62,059 2,13,23,815
Reconciliation of liability asset of defined benefit plans
[Abstract]
Defined benefit obligation, at present value 2,54,62,059 2,13,23,815 2,13,23,815
Net liability (asset) of defined benefit plans 2,54,62,059 2,13,23,815
Recognised expense of defined benefit plans [Abstract]
Current service cost, defined benefit plan 66,26,446 51,95,647
Interest cost, defined benefit plan 16,86,684 13,29,437
Actuarial gains (losses) recognised in profit or loss,
14,28,762 -16,93,933
defined benefit plan
Total post-employment benefit expense, defined benefit
68,84,368 82,19,017
plans
Actuarial assumption [Abstract]
Actuarial assumption of discount rates 625.00% 625.00%
Experience adjustments on plan assets and plan liabilities
[Abstract]
Defined benefit obligation, at present value 2,54,62,059 2,13,23,815 2,13,23,815
Net surplus (deficit) in plan -2,54,62,059 -2,13,23,815
Experience adjustments on plan liabilities -14,28,762 -5,20,186
88

01/04/2020
to
31/03/2021
Disclosure of employee benefits explanatory [TextBlock] [See below]
Description of accounting policy for defined benefit plans

Employee benefits Defined contribution plans The Company makes contributions, determined as a specified percentage of employees
salaries, in respect of qualifying employees towards provident fund and employees state insurance, which are defined contribution plans. The
Company has no obligation other than to make the specified contribution. The contributions are charged to the statement of profit and loss as
they accrue. The amount recognized as an expense towards contribution to provident fund and employee state insurance for the year
aggregated to Rs. 9,614,675/- (previous year: Rs. 11,107,572/-). Defined benefit plans The Company operates a post employment benefit
plan that provides for gratuity benefit to the employees of the Company. The gratuity plan entitles an employee, who has rendered at least
five years of continuous service, to receive one-half months salary for each year of completed service at the time of retirement/exit. The
following table sets set out the status of the gratuity plan as required under Accounting standard (AS) 15 “Employee Benefits” prescribed by
Companies (Accounting Standards) Rules, 2006, (‘the Rules’): Liability recognized in the balance sheet As at 31 March 2021 As at
31 March 2020 Present value of obligations 2,54,62,059 2,13,23,815 Fair value of plan assets -
- Net liability recognized in the balance sheet 2,54,62,059 2,13,23,815 Classification into
current/ non-current As at 31 March 2021 As at 31 March 2020 Current 29,50,660 19,26,131 Non-current
2,25,11,399 1,93,97,684 Change in present values of defined benefit obligation As at 31 March 2021 As at 31 March 2020
Opening defined benefit obligation 2,12,81,867 1,38,92,133 Current service cost 66,68,394
51,95,647 Interest cost 16,86,684 13,29,437 Actuarial loss/ (gain) (14,28,762) 16,93,933
Past service cost - - Benefits paid (27,46,125) (9,58,259) Expenses
66,26,446 51,95,647 Interest on defined benefit obligation 16,86,684 13,29,437 Net
actuarial loss/ (gain) recognized in the current year (14,28,762) 16,93,933 Past service cost -
Total expense included in "employee benefits" 68,84,368 82,19,017 Principal actuarial assumptions For the year
ended 31 March 2021 For the year ended 31 March 2020 Discount rate as at the balance sheet date 6.25% 6.25% Future salary increase
8.00% 8.00% Retirement age 58 years 58 years Experience adjustments For the year ended 31 March 2020 For the year ended 31
March 2021 Defined benefit obligation 2,11,52,891 2,54,62,058 Plan assets -
- Deficit 2,11,52,891 2,54,62,058 Experience adjustments on plan liabilities -5,20,186 -14,28,762 Experience
adjustments on plan assets - - Employee benefits Short-term employee benefits: Employee
benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits
include salaries and wages, bonus and ex-gratia. The undiscounted amount of short-term employee benefits to be paid in exchange for
employee services is recognized as an expense over the period of the service rendered by the employees. Post-employment benefits: Defined
contribution plans A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a
separate entity and has no obligation to pay any further amounts. The Group makes specified monthly contributions towards employee
provident fund to Government administered provident fund scheme which is a defined contribution plan. The Group contribution is
recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service. Defined
benefit plans The Group gratuity benefit scheme is a defined benefit plan. The Group net obligation in respect of a defined benefit plan is
calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods;
that benefit is discounted to determine its present value. Any unrecognized past service costs and the fair value of any plan assets are
deducted. The calculation of the Group obligation is performed annually by a qualified actuary using the projected unit credit method. The
Group recognizes all actuarial gains and losses arising from defined benefit plans immediately in the statement of profit and loss. All
expenses related to defined benefit plans are recognized in employee benefits expense in the statement of profit and loss. Compensated
absences Compensated absences liability is accrued based on an actuarial valuation at the balance sheet date, carried out by an independent
actuary using the projected unit credit method. To the extent the group does not have an unconditional right to defer the utilization or
encashment of the accumulated compensated absences, the liability determined based on actuarial valuation is considered to be a current
liability. Actuarial gains and losses are recognized immediately in the statement of profit and loss.
89
Description of accounting policy for defined benefit plans

Employee benefits Defined contribution plans The Company makes contributions, determined as a specified percentage of employees
salaries, in respect of qualifying employees towards provident fund and employees state insurance, which are defined contribution plans. The
Company has no obligation other than to make the specified contribution. The contributions are charged to the statement of profit and loss as
they accrue. The amount recognized as an expense towards contribution to provident fund and employee state insurance for the year
aggregated to Rs. 9,614,675/- (previous year: Rs. 11,107,572/-). Defined benefit plans The Company operates a post employment benefit
plan that provides for gratuity benefit to the employees of the Company. The gratuity plan entitles an employee, who has rendered at least
five years of continuous service, to receive one-half months salary for each year of completed service at the time of retirement/exit. The
following table sets set out the status of the gratuity plan as required under Accounting standard (AS) 15 “Employee Benefits” prescribed by
Companies (Accounting Standards) Rules, 2006, (‘the Rules’): Liability recognized in the balance sheet As at 31 March 2021 As at
31 March 2020 Present value of obligations Fair value of plan assets - - Net liability recognized in
the balance sheet Classification into current/ non-current As at 31 March 2021 As at 31 March 2020 Current 29,50,660
19,26,131 Non-current 2,25,11,399 1,93,97,684 Change in present values of defined benefit obligation
As at 31 March 2021 As at 31 March 2020 Opening defined benefit obligation Current service cost 66,68,394
51,95,647 Interest cost 16,86,684 13,29,437 Actuarial loss/ (gain) (14,28,762) 16,93,933
Past service cost - - Benefits paid (27,46,125) (9,58,259) Expenses
66,26,446 51,95,647 Interest on defined benefit obligation Net actuarial loss/ (gain) recognized in the current year
Past service cost - Total expense included in "employee benefits" Principal actuarial assumptions For the
year ended 31 March 2021 For the year ended 31 March 2020 Discount rate as at the balance sheet date Future salary increase 8.00% 8.00%
Retirement age 58 years 58 years Experience adjustments For the year ended 31 March 2020 For the year ended 31 March 2021
Defined benefit obligation 2,54,62,058 Plan assets - - Deficit 2,11,52,891
2,54,62,058 Experience adjustments on plan liabilities -14,28,762 Experience adjustments on plan assets -
Employee benefits Short-term employee benefits: Employee benefits payable wholly within twelve months of receiving employee services
are classified as short-term employee benefits. These benefits include salaries and wages, bonus and ex-gratia. The undiscounted amount of
short-term employee benefits to be paid in exchange for employee services is recognized as an expense over the period of the service
rendered by the employees. Post-employment benefits: Defined contribution plans A defined contribution plan is a post-employment benefit
plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Group
makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a
defined contribution plan. The Group contribution is recognized as an expense in the statement of profit and loss during the period in which
the employee renders the related service. Defined benefit plans The Group gratuity benefit scheme is a defined benefit plan. The Group net
obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return
for their service in the current and prior periods; that benefit is discounted to determine its present value. Any unrecognized past service costs
and the fair value of any plan assets are deducted. The calculation of the Group obligation is performed annually by a qualified actuary using
the projected unit credit method. The Group recognizes all actuarial gains and losses arising from defined benefit plans immediately in the
statement of profit and loss. All expenses related to defined benefit plans are recognized in employee benefits expense in the statement of
profit and loss. Compensated absences Compensated absences liability is accrued based on an actuarial valuation at the balance sheet date,
carried out by an independent actuary using the projected unit credit method. To the extent the group does not have an unconditional right to
defer the utilization or encashment of the accumulated compensated absences, the liability determined based on actuarial valuation is
considered to be a current liability. Actuarial gains and losses are recognized immediately in the statement of profit and loss.
90
Disclosure of employee benefits explanatory [Text Block]
Employee benefits expense
For the year

For the year ended
ended
31 March 2020
31 March 2021
Salary, wages and bonus

39,85,68,805 42,28,89,208
Contribution to provident and other funds

1,08,46,338 1,11,07,572
Staff welfare expenses

1,11,26,848 1,44,94,341
Employee stock option expense (including prior period expense amounting to Rs.
57,535,356, also refer note 3.29) 7,28,91,642 -
49,34,33,633 44,84,91,121
[300400] Notes - Employee share-based payments

01/04/2020
to
31/03/2021
Disclosure of notes on employee share-based payment arrangements explanatory Textual information (22)
91
Disclosure of notes on employee share-based payment arrangements explanatory [Text Block]
Employee Stock-based payment plans
Certain employees of the Company as entitled to stock options under the Medgenome Inc. 2014 Stock Plan,
subject to compliance with vesting conditions mentioned therein. In accordance with the Guidance Note on
"Accounting for Employee Share-based Payments" issued by the ICAl , the necessary disclosures have been
made for the period ended 31 March 2021.
Share-based payment expense
As at
Particulars
31 March 2021
2014 plan*
7,28,91,642
Reconciliation of outstanding shares options are as follows.
For the period

Particulars ending 31 March
2021
Options outstanding at the beginning of the year

-
Granted/transferred*
5,62,609
Forfeited during the year

-
Exercised during the year

1,44,238
Options outstanding at the end of year

4,18,371
Exercisable as at the end of the year

4,18,371
The weighted average share price for options exercised in the year was Rs 167.
Note: *During the current year, the Company has recorded share based payments expense amounting to Rs.
72,891,642, out of which Rs. 57,535,356 was pertaining to earlier years contribution which was made by the
Medgenome Inc., ultimate holding company of the Company for the employee stock option plan.
92
[201300] Notes - Segments
Additional geographical disclosure of revenue from customers based on customer location [Table] ..(1)
Geographical disclosure of revenue from customers based on
1 2
customer location [Axis]
01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of reportable segments [Abstract]
Disclosure of secondary reportable segments [Abstract]
Additional geographical disclosure of
revenue from customers based on customer
location [Abstract]
Geographical disclosure of revenue from
customers based on customer location
[LineItems]
Description of revenue from external
India India USA USA
customers based on customer location
Revenue from external customers (A) 91,39,40,641 77,50,95,964 (B) 70,11,84,112 28,77,44,625
Footnotes
(A) The Revenue is generated from: 1. academics and research 2. clinical diagnostics
(B) The Revenue is generated from: 1. academics and research 2. clinical diagnostics
Additional geographical disclosure of revenue from customers based on customer location [Table] ..(2)
Geographical disclosure of revenue from customers based on customer location [Axis] 3
01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of reportable segments [Abstract]
Disclosure of secondary reportable segments [Abstract]
Additional geographical disclosure of revenue from customers based on customer
location [Abstract]
Geographical disclosure of revenue from customers based on customer location
[LineItems]
Description of revenue from external customers based on customer location Rest of the world Rest of the world
Revenue from external customers (A) 2,75,54,242 2,42,28,427
Footnotes
(A) The Revenue is generated from: 1. academics and research 2. clinical diagnostics
01/04/2020
to
31/03/2021
Disclosure of enterprise's reportable segments explanatory [TextBlock] [See below]
93
Disclosure of enterprise's reportable segments explanatory [Text Block]
Segment reporting
Business segment
The Group operation predominantly relate to providing molecular diagnostic testing services for
genetic diseases and drug metabolism. The Group has evaluated its service offerings and has
concluded that risk and rewards of all the services are identical. Accordingly, the Board of
Directors and the Chief Executive Officer of the Company review the performance of the Group as
on primarily segment i.e. molecular diagnostic testing services.
Geographical segment
Secondary segment reporting is performed on the basis of geographical segmentation as the Group.
The Group geographic segmentation is based on location of customer. The Group has classified its
geographical presence in three categories India, USA and rest of the world.
For the year For the year ended

ended
31 March 2021 31 March 2020
Revenue
- India
91,39,40,641 77,50,95,964
- USA
70,11,84,112 28,77,44,625
- Rest of the world

2,75,54,242 2,42,28,427
1,64,26,78,995 1,08,70,69,016
Segment assets
- India
55,75,70,988 56,20,55,781
- USA
- 3,83,65,241
- Rest of the world

1,07,83,837 37,96,352
-Unallocated
47,59,75,749 37,63,89,118
94
1,04,43,30,574 98,06,06,492
Capital expenditure
- India
9,99,88,760 8,07,27,780
- USA
- -
- Rest of the world

- -
9,99,88,760 8,07,27,780
Depreciation
- India
16,18,16,826 19,03,46,816
- USA
- -
- Rest of the world

- -
16,18,16,826 19,03,46,816
95
[201600] Notes - Related party
Disclosure of relationship and transactions between related parties [Table] ..(1)

Categories of related parties [Axis] 1 2
01/04/2020 01/04/2019 01/04/2020 01/04/2019
to to to to
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of relationship and transactions between
related parties [Abstract]
Disclosure of relationship and transactions between
related parties [LineItems]
Name of related party MedGenome Inc. MedGenome Inc. Sreedhar Santhosh Sreedhar Santhosh
Country of incorporation or residence of related
UNITED STATES UNITED STATES INDIA INDIA
party
Permanent account number of related party BIVPS0762B BIVPS0762B
Enterprises which Enterprises which are
are owned, or have owned, or have
significant significant influence
influence of or are of or are partners Key Management Key Management
Description of nature of related party relationship partners with Key w i t h K e y Personnel Personnel
management management
personnel and their personnel and their
relatives relatives
Description of nature of transactions with related Enterprise where Enterprise where Key management Key management
party control exists control exists personnel personnel
Related party transactions [Abstract]
Purchases of goods related party transactions 1,07,11,469 1,86,50,363
Revenue from sale of goods related party
69,07,53,080 21,38,40,420
transactions
Advances taken during year related party
80,90,10,714 24,75,29,250
transactions
Reimbursement of expenses incurred on
behalf of company during year related 2,22,36,973
party transactions
Other related party transactions expense 99,239 (A) 12,250
Amount written off during period in respect
0 0 0 0
of debts due from related parties
Amount written back during period in respect
0 0 0 0
of debts due to related parties
Footnotes
(A) Travelling expenses : 0
96
Disclosure of relationship and transactions between related parties [Table] ..(2)

Categories of related parties [Axis] 3 4
01/04/2020 01/04/2019 01/04/2020
to to to
31/03/2021 31/03/2020 31/03/2021
Disclosure of relationship and transactions between related parties
[Abstract]
Disclosure of relationship and transactions between related parties
[LineItems]
SHENOY'S CARE
Name of related party Mahesh Pratapneni Mahesh Pratapneni
PRIVATE LIMITED
Country of incorporation or residence of related party INDIA INDIA INDIA
Permanent account number of related party ARIPP9271D ARIPP9271D
CIN of related party U85300KL2018PTC053588
Enterprises which are
owned, or have significant
Key Management Key Management
Description of nature of related party relationship Personnel Personnel
influence of or are partners
with Key management
personnel and their relatives
Key management Key management Enterprise where control
Description of nature of transactions with related party personnel personnel exists
Related party transactions [Abstract]
Other related party transactions expense 13,898 19,71,039 (A) 3,27,541
Amount written off during period in respect of debts due from
0 0 0
related parties
Amount written back during period in respect of debts due to
0 0 0
related parties
Footnotes
(A) Sequencing Services: 265208 Amount paid against Sequencing Services: 62333
01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of notes on related party explanatory [TextBlock] [See below]
Whether there are any related party transactions during year Yes Yes
97
Disclosure of notes on related party explanatory [Text Block]

3.28: Related parties
Enterprise where control exists
1.Enterprise where control exists
MedGenome Inc. Holding Company
SciGenom Labs Private Limited Entity controlled by Director
Shenoy Care Pvt Ltd. Entity controlled by Director
2. Key management personnel
Mr. Sreedhar Santhosh Director
Ms. Balamani Amma MR Director
Mr. Mahesh Pratapneni Director
Mr. Shankar Prasad Director
Mr. Prasad Shejale Director
Mr. Padmanbha Shenoy Director
3. The following is the summary of transactions with related parties
For the year ended For the year ended

Nature of transaction
31 March 2021 31 March 2020
MedGenome Inc.
Advance received 80,90,10,714 24,75,29,250
Revenue from academics and research 69,07,53,080 21,38,40,420
Reimbursement of expense/ professional fee
222,36,973 -
98
Purchase of consumables 1,07,11,469 1,86,50,363
Sreedhar Santhosh
Travelling expenses 99,239 12,250
Mahesh Pratapneni
Travelling expenses 13,898 19,71,039
Shenoy Care Pvt Ltd.
Sequencing Services 2,65,208 -
Amount paid against Sequencing Services 62,333 -
Loan from Director
Mr.Padmanabha Shenoy - 21,00,000
4. Balances payable to related party as at the balance sheet date:
As at As at
31 March 2021 31 March 2020
MedGenome Inc.
Advance from customer 28,16,91,249 17,27,20,317
Creditor for expenses 5,18,84,344 1,97,74,914
Shenoy Care Pvt Ltd.
Sequencing Services 2,02,875 -
Key Management Personnel
Loan repayable to :
Mr.Padmanabha Shenoy 21,00,000 21,00,000
99
Travel expenses payable to:
Mr. Sreedhar Santhosh 64,634 1,395
[201400] Notes - Leases
Disclosure of minimum operating lease payments by lessee [Table] ..(1)

Later than one year and not later than
Maturity [Axis] Not later than one year [Member]
five years [Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of finance lease and operating lease by
lessee [Abstract]
Disclosure of operating lease by lessee [Abstract]
Disclosure of minimum operating lease payments
by lessee [Abstract]
Disclosure of operating lease by lessee
[LineItems]
Minimum operating lease payments payable 2,00,40,146 1,27,87,228 6,77,45,168 1,04,17,966
Disclosure of minimum operating lease payments by lessee [Table] ..(2)

Maturity [Axis] Later than five years [Member]
31/03/2021 31/03/2020
Disclosure of finance lease and operating lease by lessee [Abstract]
Disclosure of operating lease by lessee [Abstract]
Disclosure of minimum operating lease payments by lessee [Abstract]
Disclosure of operating lease by lessee [LineItems]
Minimum operating lease payments payable 0 0

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of leases explanatory [TextBlock] [See below]
Whether any operating lease has been converted to financial lease or
No No
vice-versa
100
Disclosure of leases explanatory [Text Block]
Operating leases
Assets acquired under leases other than finance leases are classified as operating leases. The total lease rentals (including scheduled
rental increases) in respect of an asset taken on operating lease are charged to the statement of profit and loss on a straight line basis
over the lease term unless another systematic basis is more representative of the time pattern of the benefit.
[300300] Notes - Earnings per share

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Disclosure of earnings per share explanatory [TextBlock] [See below]
Adjustments of numerator to calculate basic earnings per share [Abstract]
Adjustments of numerator to calculate diluted earnings per share [Abstract]
Disclosure of earnings per share explanatory [Text Block]
Earnings per share (‘EPS’)
The basic earnings per share is computed by dividing the net profit after tax for the period by the weighted average number of equity
shares outstanding during the period. Diluted earnings per share, if any is computed using the weighted average number of equity
shares and dilutive potential equity share outstanding during the period except when the results would be anti-dilutive. Diluted
potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date.
[201900] Notes - Income taxes

01/04/2020
to
31/03/2021
Disclosure of notes on income taxes explanatory [TextBlock] [See below]
101
Disclosure of notes on income taxes explanatory [Text Block]
Taxation
Income-tax expense comprises current tax (i.e. amount of tax for the period determined in accordance with the income-tax law) and
deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the
period). Income-tax expense is recognized in the statement of profit and loss except that tax expense related to items recognized
directly in reserves is also recognized in those reserves.
Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the applicable tax rates
and tax laws. Deferred tax is recognized in respect of timing differences between taxable income and accounting income i.e.
differences that originate in one period and are capable of reversal in one or more subsequent periods. The deferred tax charge or
credit and the corresponding deferred tax liabilities or assets are recognized using the tax rates and tax laws that have been enacted
or substantively enacted by the balance sheet date. Deferred tax assets are recognized only to the extent there is reasonable certainty
that the assets can be realized in future; however, where there is unabsorbed depreciation or carried forward loss under taxation laws,
deferred tax assets are recognized only if there is a virtual certainty supported by convincing evidence that sufficient future taxable
income will be available against which such deferred tax assets can be realized. Deferred tax assets are reviewed as at each balance
sheet date and written down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be
realized.
Assets and liabilities representing current and deferred tax are disclosed on a net basis when there is a legally enforceable right to set
off and management intends to settle the asset and liability on a net basis.
Minimum Alternative Tax (‘MAT’) under the provisions of the Income-tax Act, 1961 is recognized as current tax in the statement of
profit and loss. The credit available under the Act in respect of MAT paid is recognized as an asset only when and to the extent there
is convincing evidence that the Group will pay normal income tax during the period for which the MAT credit can be carried
forward for set-off against the normal tax liability. MAT credit recognized as an asset is reviewed at each balance sheet date and
written down to the extent the aforesaid convincing evidence no longer exists.
The Group offsets, on a year on year basis, the current tax assets and liabilities, where it has a legally enforceable right and where it
intends to settle such assets and liabilities on a net basis.
[202600] Notes - Consolidated financial statements
Disclosure of details of entities consolidated [Table] ..(1)

Entities consolidated [Axis] 1.
01/04/2020
to
31/03/2021
Disclosure of additional information consolidated financial statements [Abstract]
Disclosure of additional information consolidated financial statements [LineItems]
Immucare
Name of entity consolidated Diagnostics Private
Limited
Type of entity consolidated Indian Subsidiary
Amount of net assets of entity consolidated 1,28,51,172
Net assets of entity as percentage of consolidated net assets 65.00%
Amount of share in profit or loss of entity consolidated 0
Share in profit or loss of entity as percentage of consolidated profit or loss 0.00%
102
Disclosure of details of subsidiaries [Table] ..(1)

Subsidiaries [Axis] 1.
01/04/2020
to
31/03/2021
Disclosure of details of subsidiaries [Abstract]
Disclosure of details of subsidiaries [LineItems]
Immucare
Name of subsidiary consolidated Diagnostics Private
Limited
Country of incorporation or residence of subsidiary consolidated INDIA
Proportion of ownership interest in subsidiary consolidated 65.00%
Proportion of voting power held in subsidiary consolidated 0.00%
Description of nature of relationship with subsidiary where parent has directly or indirectly
NA
less than half of voting power

01/04/2020
to
31/03/2021
Disclosure of notes on consolidated financial statements explanatory
[TextBlock]
Whether consolidated financial statements is applicable on company Yes
Description of reason for not consolidating subsidiary NA
Description of fact that uniform accounting policies are not adopted for
NA
consolidated financial statements
Proportion of items in consolidated financial statements to which
0.00%
different accounting policies have been applied
Disclosure of details of subsidiaries explanatory [TextBlock]
Disclosure of additional information consolidated financial statements
[TextBlock]
[201500] Notes - Impairment

01/04/2020
to
31/03/2021
Disclosure of impairment of assets explanatory [TextBlock] [See below]
103
Disclosure of impairment of assets explanatory [Text Block]
Impairment of plant and equipment
The Group assesses at each balance sheet date whether there is any indication that an asset or a group of assets comprising a cash
generating unit may be impaired. If any such indication exists, the Group estimates the recoverable amount of the asset. For an asset
or group of assets that does not generate largely independent cash in-flows, the recoverable amount is determined for the
cash-generating unit to which the asset belongs. If such recoverable amount of the asset or the recoverable amount of the cash
generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount.
The reduction is treated as an impairment loss and is recognized in the statement of profit and loss. If at the balance sheet date there
is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is
reflected at the recoverable amount subject to a maximum of depreciable historical cost. An impairment loss is reversed only to the
extent that the carrying amount of asset does not exceed the net book value that would have been determined; if no impairment loss
had been recognized.
The recoverable amount of an asset or cash generating unit (CGU) is the greater of its value in use and its net selling price. In
assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects
current market assessments of the time value of money and the risks specific to the asset or CGU.
Impairment losses are recognized in statement of profit or loss. However, an impairment loss on a revalued asset is recognized
directly against any revaluation surplus to the extent that the impairment loss does not exceed the amount held in the revaluation
surplus for that same asset.
[202100] Notes - Other provisions, contingent liabilities and contingent assets
Disclosure of contingent liabilities [Table] ..(1)

Indemnity for guarantees given by bank
Classes of contingent liabilities [Axis] Other contingent liabilities [Member]
[Member]
31/03/2021 31/03/2020 31/03/2021 31/03/2020
Disclosure of contingent liabilities [Abstract]
Disclosure of contingent liabilities [LineItems]
Estimate of financial effect of contingent
22,50,53,894 30,01,50,286 (A) 1,66,64,269 (B) 6,03,21,485
liabilities
Footnotes
(A) Performance and financial guarantee given by banks on behalf of the Company
(B) Performance and financial guarantee given by banks on behalf of the Company
Disclosure of contingent liabilities [Table] ..(2)

Contingent liability on disputed income
Classes of contingent liabilities [Axis]
tax [Member]
31/03/2021 31/03/2020
Disclosure of contingent liabilities [Abstract]
Disclosure of contingent liabilities [LineItems]
Estimate of financial effect of contingent liabilities (A) 20,83,89,625 (B) 23,98,28,801
Footnotes
(A) Contingent liabilities to the extent not provided for: Disputed demand for income tax and service tax
(B) Contingent liabilities to the extent not provided for: Disputed demand for income tax and service tax
104

01/04/2020
to
31/03/2021
Disclosure of notes on other provisions, contingent liabilities and Textual information (29)
contingent assets explanatory [TextBlock] [See below]
Disclosure of other provisions explanatory [TextBlock] [See below]
Disclosure of contingent liabilities explanatory [TextBlock]
Disclosure of notes on other provisions, contingent liabilities and contingent assets explanatory [Text Block]
Contingent liabilities
A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will
not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not
warrant provisions, but are disclosed unless the possibility of outflow of resources is remote.
105
Disclosure of other provisions explanatory [Text Block]
Provisions
A provision is recognized if, as a result of a past event, the Group has a present obligation that can be estimated reliably, and it is
probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognized at the best
estimate of the expenditure required to settle the present obligation at the balance sheet date. The provisions are measured on an
undiscounted basis.
Onerous contracts
A contract is considered as onerous when the expected economic benefits to be derived by the Group from the contract are lower
than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the
lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision
is established, the Group recognizes any impairment loss on the assets associated with that contract.
Contingencies
Provision in respect of loss contingencies relating to claims, litigation, assessment, fines, penalties, etc. are recognized when it is
probable that a liability has been incurred and the amount can be estimated reliably.
[202700] Notes - Cash flow statements

01/04/2020 01/04/2019
to to 31/03/2019
31/03/2021 31/03/2020
Disclosure of cash flow statement explanatory [TextBlock] [See below]
Cash and cash equivalents if different from balance sheet [Abstract]
Cash and cash equivalents cash flow statement (A) 5,91,39,858
5,56,37,440 1,76,89,133
Bank overdrafts classified as cash equivalents -65,28,151 -47,10,563

Total cash and cash equivalents 6,56,68,009 6,03,48,003
Income taxes paid (refund) [Abstract]
Income taxes paid (refund), classified as operating activities -2,55,65,979 3,55,94,292
Income taxes paid (refund), classified as investing activities 0 0
Income taxes paid (refund), classified as financing activities 0 0
Total income taxes paid (refund) -2,55,65,979 3,55,94,292
Footnotes
(A) For the purpose of Cash flow statement, Cash and cash equivalents include following: ParticularsAs at 31 March 2021As at 31
March 2020 Cash and Bank balance 6,56,68,009 6,03,48,003 Overdraft facility with bank -65,28,151-47,10,563 Total 5,91,39,858
5,56,37,440
106
Disclosure of cash flow statement explanatory [Text Block]
Cash flow statement
Cash flows are reported using the indirect method, whereby net profits/loss before tax is adjusted for the effects of transactions of a
non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue
generating, investing and financing activities of the group are segregated.
[100200] Statement of profit and loss

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Statement of profit and loss [Abstract]
Disclosure of revenue from operations [Abstract]
Disclosure of revenue from operations for other than finance company
[Abstract]
Revenue from sale of products 0 0
Revenue from sale of services 164,26,78,995 108,70,69,016
Total revenue from operations other than finance company 164,26,78,995 108,70,69,016
Total revenue from operations 164,26,78,995 108,70,69,016
Other income 3,01,45,068 1,09,63,584
Total revenue 167,28,24,063 109,80,32,600
Expenses [Abstract]
Cost of materials consumed 42,85,21,609 46,93,22,833
Changes in inventories of finished goods, work-in-progress and
0 0
stock-in-trade
Employee benefit expense 49,34,33,633 44,84,91,121
Finance costs 4,31,89,689 2,13,10,531
Depreciation, depletion and amortisation expense [Abstract]
Depreciation expense (A) 16,18,16,826 (B) 19,03,46,816
Total depreciation, depletion and amortisation expense 16,18,16,826 19,03,46,816
Expenditure on production, transportation and other expenditure
4,82,74,295 3,81,31,309
pertaining to exploration and production activities
CSR expenditure 0 0
Other expenses 39,26,29,016 41,51,94,195
Total expenses 156,78,65,068 158,27,96,805
Total profit before prior period items, exceptional items, extraordinary
10,49,58,995 -48,47,64,205
items and tax
Total profit before extraordinary items and tax 10,49,58,995 -48,47,64,205
Total profit before tax 10,49,58,995 -48,47,64,205
Tax expense [Abstract]
Current tax (C) 0 0
Total tax expense 0 0
Total profit (loss) for period from continuing operations 10,49,58,995 -48,47,64,205
Total profit (loss) for period before minority interest 10,49,58,995 -48,47,64,205
Profit (loss) of minority interest 0 43,86,359
Total profit (loss) for period 10,49,58,995 -48,03,77,846
Earnings per equity share [Abstract]
Basic earning per equity share [INR/shares] 41.83 [INR/shares] -191.44
Diluted earnings per equity share [INR/shares] 41.83 [INR/shares] -191.44
Nominal value of per equity share [INR/shares] 10 [INR/shares] 10
107
Footnotes
(A) Depreciation and amortization
(B) Depreciation and amortization
(C) Current tax: 1,77,49,787 Less : Minimum alternative tax (MAT) credit entitlement : (1,77,49,787)
108
[300500] Notes - Subclassification and notes on income and expenses

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Subclassification and notes on income and expense explanatory [TextBlock]
Disclosure of revenue from sale of products [Abstract]
Revenue from sale of products [Abstract]
Total revenue from sale of products 0 0
Disclosure of revenue from sale of services [Abstract]
Revenue from sale of services [Abstract]
Revenue from sale of services, gross (A) 164,26,78,995 (B) 108,70,69,016
Total revenue from sale of services 164,26,78,995 108,70,69,016
Disclosure of other income [Abstract]
Interest income [Abstract]
Interest income on current investments [Abstract]
Interest on fixed deposits, current investments (C) 1,31,88,448 (D) 1,09,63,584
Total interest income on current investments 1,31,88,448 1,09,63,584
Total interest income 1,31,88,448 1,09,63,584
Dividend income [Abstract]
Total dividend income 0 0
Other non-operating income [Abstract]
Miscellaneous other non-operating income (E) 1,69,56,620
0
Total other non-operating income 1,69,56,620 0

Total other income 3,01,45,068 1,09,63,584
Disclosure of finance cost [Abstract]
Interest expense [Abstract]
Interest expense short-term loans [Abstract]
Interest expense short-term loans, others (F) 4,31,89,689 (G) 2,13,10,531
Total interest expense short-term loans 4,31,89,689 2,13,10,531
Total interest expense 4,31,89,689 2,13,10,531
Total finance costs 4,31,89,689 2,13,10,531
Employee benefit expense [Abstract]
Salaries and wages (H) 39,85,68,805 (I) 42,28,89,208
Managerial remuneration [Abstract]
Remuneration to directors [Abstract]
Total remuneration to directors 0 0
Total managerial remuneration 0 0
Contribution to provident and other funds [Abstract]
Contribution to provident and other funds for others 1,08,46,338 1,11,07,572
Total contribution to provident and other funds 1,08,46,338 1,11,07,572
Expense on employee stock option scheme and employee stock purchase plan (J) 7,28,91,642
0
Staff welfare expense 1,11,26,848 1,44,94,341

Total employee benefit expense 49,34,33,633 44,84,91,121
Breakup of other expenses [Abstract]
Consumption of stores and spare parts 0 0
Power and fuel 0 0
Rent 2,57,10,968 2,58,64,410
Repairs to building (K) 1,10,69,108 (L) 1,96,44,336

Repairs to machinery 6,03,87,949 6,06,91,792
Insurance 1,67,560 0
Rates and taxes excluding taxes on income [Abstract]
Other cess taxes 4,88,42,561 3,93,92,297
Total rates and taxes excluding taxes on income 4,88,42,561 3,93,92,297
Electricity expenses 1,77,77,324 2,13,83,133
Telephone postage 1,15,12,650 1,50,57,377
Printing stationery 37,59,296 52,22,593
Travelling conveyance 3,06,51,191 5,16,48,489
Legal professional charges 8,00,35,395 5,92,07,041
109
Safety security expenses (M) 5,83,162

0
Directors sitting fees 0 0

Bank charges 4,31,199 7,02,745
Guest house expenses (N) 2,97,513

0
Advertising promotional expenses (O) 2,59,42,059 (P) 3,10,58,501

Cost royalty (Q) 11,500 (R) 71,08,232
Provision bad doubtful debts created 0 0
Provision bad doubtful loans advances created 0 0
Write-off assets [Abstract]
Miscellaneous expenditure written off [Abstract]
Total miscellaneous expenditure written off 0 0
Bad debts written off 0 0
Bad debts advances written off 0 0
Loss on disposal of intangible asset 0 0
Loss on disposal, discard, demolishment and destruction of depreciable
0 0
tangible asset
Payments to auditor [Abstract]
Payment for audit services (S) 15,53,096 (T) 15,00,000
Payment for taxation matters 1,50,000 1,50,000
Total payments to auditor 17,03,096 16,50,000
Miscellaneous expenses (U) 7,37,46,485 (V) 7,65,63,249

Total other expenses 39,26,29,016 41,51,94,195
Breakup of expenditure on production, transportation and other
expenditure pertaining to exploration and production activities
[Abstract]
Total expenditure on production, transportation and other
4,82,74,295 3,81,31,309
expenditure pertaining to exploration and production activities
Current tax [Abstract]
Total current tax (W) 0 0
Footnotes
(A) Revenue from academics and research: 880795160 Revenue from clinical diagnostics:761883835
(B) Revenue from academics and research: 376759701 Revenue from clinical diagnostics:710309315
(C) Interest income
(D) Interest income
(E) Miscellaneous income: 306824 Foreign exchange gain, net: 16649796
(F) Interest expense
(G) Interest expense
(H) Salary, wages and bonus
(I) Salary, wages and bonus
(J) Employee stock option expense (including prior period expense amounting to Rs. 57,535,356, also refer note 3.29) 3.29: Note:
*During the current year, the Company has recorded share based payments expense amounting to Rs. 72,891,642, out of which Rs.
57,535,356 was pertaining to earlier years contribution which was made by the Medgenome Inc., ultimate holding company of the
Company for the employee stock option plan.
(K) Repairs and maintenance - others
(L) Repairs and maintenance - others
(M) Security Charges
(N) House Keeping Charges
(O) Business promotion expense
(P) Business promotion expense
(Q) Royalty expenses
(R) Royalty expenses
(S) 'Statutory audit (including out of pocket expenses) *Excluding GST/ service tax
(T) 'Statutory audit (including out of pocket expenses) *Excluding GST/ service tax
(U) Logistics cost: 39014957 Recruitment cost:2177189 Miscellaneous expenses: 32554336
(V) Logistics cost: 40353400 Recruitment cost: 2026541 Foreign exchange loss, net: 25734674 Miscellaneous expenses: 8448634
(W) Current tax: 1,77,49,787 Less : Minimum alternative tax (MAT) credit entitlement : (1,77,49,787)
110
[300600] Notes - Additional information statement of profit and loss

01/04/2020 01/04/2019
to to
31/03/2021 31/03/2020
Additional information on profit and loss account explanatory [TextBlock]
Total changes in inventories of finished goods, work-in-progress and
0 0
stock-in-trade
Revenue other services (A) 164,26,78,995 (B) 108,70,69,016
Total gross income from services rendered (C) 164,26,78,995 (D) 108,70,69,016
Value of imports of raw materials (E) 37,02,11,880 (F) 33,25,16,824
Value of imports of capital goods 7,01,01,745 3,93,97,956
Total value of imports calculated on CIF basis 44,03,13,625 37,19,14,780
Expenditure on royalty 0 71,08,232
Expenditure on professional and consultation fees 2,28,62,846 8,94,203
Expenditure on other matters (G) 37,07,29,009 (H) 33,25,16,824

Expenditure on dividend paid 0 0
Total expenditure in foreign currency 39,35,91,855 34,05,19,259
Total amount of dividend remitted in foreign currency 0 0
Earnings on other income (I) 72,87,38,354 (J) 30,49,61,460

Total earnings in foreign currency 72,87,38,354 30,49,61,460
Total revenue from sale of products 0 0
Domestic revenue services 164,26,78,995 108,70,69,016
Total revenue from sale of services 164,26,78,995 108,70,69,016
Capital expenditure in foreign currency (K) 39,35,91,855 (L) 34,05,19,259

Gross value of transaction with related parties as per AS-18 72,41,42,200 23,44,74,072
Bad debts of related parties as per AS-18 0 0
Footnotes
(A) Revenue from academics and research:880795160 Revenue from clinical diagnostics: 761883835
(B) Revenue from academics and research: 376759701 Revenue from clinical diagnostics: 710309315
(C) Revenue from academics and research: 880795160 Revenue from clinical diagnostics:761883835
(D) Revenue from academics and research: 376759701 Revenue from clinical diagnostics:710309315
(E) Lab consumables
(F) Lab consumables
(G) Purchases: 370211880, License: 517129
(H) Purchases
(I) Revenue from academics and research:718529545 Revenue from clinical diagnostics: 10280809
(J) Revenue from academics and research:294467669 Revenue from clinical diagnostics: 10496791
(K) Purchases= Rs. 370211880 Professional; fees= 22862846 License=517129 Royalty-nil
(L) Purchases= Rs. 332516824 Professional; fees= 894203 License=nil Royalty-7108232
[300100] Notes - Revenue

01/04/2020
to
31/03/2021
Disclosure of revenue explanatory [TextBlock] [See below]
111
Disclosure of revenue explanatory [Text Block]
Revenue recognition
Revenue is primarily derived from rendering of molecular diagnostic testing services.
Revenue is recognized when there is conclusive evidence of a contractual arrangement with customers, services have been rendered,
the fee is fixed or determinable and collectability is reasonably assured. Conclusive evidence of an arrangement is established when
the group enters into an agreement with its customers with terms and conditions which describe the services and the related
payments are legally enforceable. The Group considers revenue to be determinable when the services have been provided in
accordance with the agreement.
Revenue from services provided to academic and research partners is based on the price per test mentioned in the agreements entered
into with them. Revenue is recognized upon completion of test results and issue of reports, provided the consideration is reliably
determinable and no significant uncertainty exists regarding the collection of the consideration.
Revenue from retail samples represents sequencing services provided to patient referred by hospitals, reports of which is used by the
doctors to plan treatment of patient. Revenue for retail samples are recognized as and when services are rendered to various
customers.
Unbilled revenues' included in other current assets represent cost and earnings in excess of billings as at the balance sheet date.
'Unearned revenues' included in current liabilities represent billing in excess of revenue recognized.
Interest income is recognized using the time-proportion method, based on the rates implicit in the transaction.
Revenue from operations:
For the year ended For the year ended

31 March 2021 31 March 2020
Revenue from academics and research 88,07,95,160 37,67,59,701
Revenue from clinical diagnostics 76,18,83,835 71,03,09,315
1,64,26,78,995 1,08,70,69,016
112

MedGenome Labs Consolidated Financial Statements 2020-21

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

MedGenome Labs Consolidated Financial Statements 2020-21

Uploaded by

Copyright:

Available Formats

MEDGENOME LABS LIMITED

Consolidated Financial Statements for period 01/04/2020 to 31/03/2021

[400100] Disclosure of general information about company

[400200] Disclosures - Auditors report

Details regarding auditors [Table] ..(1)

Unless otherwise specified, all monetary values are in INR

Textual information (1)

Disclosure in auditor’s report explanatory [Text Block]

INDEPENDENT AUDITORS REPORT

To the Members of MedGenome Labs Limited

Report on the Audit of Consolidated Financial Statements

Basis for Opinion

Auditors Responsibilities for the Audit of the Consolidated Financial Statements

B S R & Associates LLP

Report on Other Legal and Regulatory Requirements

Report on Other Legal and Regulatory Requirements (continued)

for B S R & Associates LLP

Firm's Registration No.: 116231W/W-100024

Date: 15 December 2021

Managements Responsibility for Internal Financial Controls

Auditors Responsibility (continued)

Meaning of Internal Financial controls with Reference to Consolidated Financial Statements

For B S R & Associates LLP

Firm Registration No. 116231W/W-100024

Membership No.: 067829

Date: 15 December 2021

[100100] Balance sheet

Minority interest (A) 0

Trade payables (C) 21,26,12,479

Other current liabilities 46,96,93,264 45,79,24,282

[100400] Cash flow statement, indirect

Other adjustments for non-cash items (A) 12,39,450

Total adjustments to profit (loss) 26,19,72,676 21,94,38,073

Other inflows (outflows) of cash (I) -1,12,80,442 (J) -32,12,750

Proceeds from borrowings 0

Other inflows (outflows) of cash (N) -4,31,89,689 (O) -2,13,10,531

[200100] Notes - Share capital

Disclosure of classes of share capital [Table] ..(1)

Total decrease in number of shares during

Original paid-up value of forfeited shares 0 0 0 0

Disclosure of classes of share capital [Table] ..(2)

Amount of preferential allotment issue arising out of conversion of

Unless otherwise specified, all monetary values are in INR

Textual information (2)

Disclosure of notes on share capital explanatory [Text Block]

Issued, subscribed and paid-up

Number Amount Amount

At the commencement of the year 25,09,291 2,50,92,910 25,09,291 2,50,92,910

Issued during the year - - - -

At the end of the year 25,09,291 2,50,92,910 25,09,291 2,50,92,910

b) Rights, preferences and restrictions attached to equity shares:

c) Shares held by holding company

Number % age Number % age

Equity share of Rs 10 each fully paid-up held by

MedGenome Inc. 24,32,104 96.92% 24,32,104 96.92%

d) Particulars of shareholders holding more than 5% shares of a class of shares

Number % age Number % age

Equity share of Rs 10 each fully paid-up held by

MedGenome Inc. 24,32,104 96.92% 24,32,104 96.92%

[200200] Notes - Reserves and surplus

Statement of changes in reserves [Table] ..(1)

(A) Expense during the year

Statement of changes in reserves [Table] ..(2)